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Introduction: Tuberculosis in the 21st Century  21 
 22 
‘Knowing is not enough; we must apply.  Willing is not enough; we must do.’ 23 
Goethe 24 
 25 
Progress against tuberculosis: moving forward, but not fast enough  26 
In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a public health emergency.1 27 
WHO urged governments worldwide to significantly scale up their TB control efforts and within a year  28 
unveiled ‘directly observed treatment, short course,’ or DOTS, as its solution to the problem. DOTS, 29 
which used direct observation to improve adherence to a rifampicin-based standardized treatment 30 
regimen of 6-9 months, also required diagnosing TB by sputum smear and reporting cases and 31 
treatment outcomes to public health authorities. Unfortunately, the original DOTS framework largely 32 
ignored smear-negative TB, extrapulmonary TB, latent tuberculosis infection (LTBI), childhood TB, and 33 
drug-resistant TB (DR-TB). The DOTS approach, while perhaps fit to budget constraints, was neither 34 
comprehensive enough nor sufficient to curtail ongoing TB transmission. The emphasis on directly 35 
observed treatment was also inimical to delivery of person-centered care.  The expanding HIV epidemic 36 
and the growth of DR TB further undermined the DOTS  strategy, which was hampered by imprecise 37 
diagnostic tools and passive case detection.   38 
 39 
Despite gains made against the TB epidemic since the introduction of DOTS—and subsequently, an 40 
enhanced strategy  by WHO to intensify TB control efforts2—the potential to dramatically reduce the 41 
rates of TB incidence and mortality worldwide as first proposed 25 years ago has not been realized.  42 
Dismayed by this lack of progress, 2014, the global TB community outlined The End  TB strategy, that has 43 
been incorporated into the   UN Sustainable Development Goals (SDGs).  By 2035, the strategy aims to 44 
reduce TB deaths to 95% of 2015 levels by 2035 and cut TB incidence to 90% of 2015 levels by 2035, and 45 
to  ensure that no families face catastrophic  costs due to tuberculosis.3,4   Tragically, the global burden 46 
of TB in 2019 remains substantial and, for reasons outlined below, those targets will not be attained 47 
without urgent corrective action. 48 
 49 
TB-related mortality and the persistent burden of TB infection and disease 50 
TB-related mortality: TB remains a global public health emergency, responsible for more deaths than 51 
any other infectious disease. While globally, the TB mortality rate has declined approximately 3 percent 52 
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per year since 2000, or 37 percent overall between 2000 and 2017,5 this decline reflects a substantial 53 
progress in the number of patients diagnosed and treated. Moreove, it aslo occurred as poverty-related 54 
drivers of TB decreased and economies grew. As evidence of this Ethiopia, Viet Nam,  Zimbabwe and 55 
Côte d’Ivoire all achieved annual average rates of decline in TB mortality of more than 6% between 2000 56 
and 2017 (Table 1). This progress aside, however, TB mortality rates, especially among people living with 57 
HIV and in children are still substantial.5,6 Furthermore, rates of TB mortality have declined much more 58 
slowly than for most other infectious diseases (Appendix Table xx), and the declines are far less in low- 59 
and lower-middle income countries compared with elsewhere (Table 2). Three-quarters of all TB deaths 60 
occur within just eight countries (Appendix Figure xx). In many parts of sub-Saharan Africa and 61 
Southeast Asia, TB remains a leading cause of years-of-life lost. Moreover, TB ranks as the 9th leading 62 
cause of death and the 12th leading cause of years-of-life lost worldwide.7 63 
 64 
TB incidence: An estimated 10 million people (90 percent adults, 58 percent male) became ill with TB in 65 
2017. Eight countries in Southeast Asia and Africa (India, Indonesia, China, the Philippines, Pakistan, 66 
South Africa, Bangladesh and Nigeria) accounted for two-thirds of all new cases worldwide. Overall, TB 67 
incidence has fallen approximately 1.4% per year since 2000 and 2% per year since 2015 – far less than 68 
the rate needed to achieve WHO End TB targets5  (an annual incidence rate decline of 4-5% by 2020 and 69 
10% by 2025 to achieve the milestone case reductions) and less than declining trends in mortality.  The 70 
overall slow decline in TB burden suggests that TB programs, while reducing deaths, are insufficient to 71 
overcome poverty-related drivers that substantially impact the epidemic.8  Modeling suggests that to 72 
avert transmission, individuals at risk must be identified and provided effective preventive therapy, and 73 
individuals with less infectious, early TB must be diagnosed and provided immediate treatment.9,10 74 
 75 
TB Prevalence: Between 2000 and 2016, 32 national TB prevalence surveys were performed in 26 76 
countries.5 These studies consistently found a higher prevalence of TB than previous estimates based on 77 
less precise information such as case notifications. The upwardly revised incidence estimates highlighted 78 
large numbers of undiagnosed or unreported TB cases in many countries. Prevalence surveys also 79 
revealed that people with TB often sought care for TB symptoms that health care workers failed to 80 
identify. Other individuals did not recognize the seriousness of their symptoms and had not sought care. 81 
All prevalence surveys in the last decade have found a higher burden of TB among men, with 82 
male:female ratios ranging from 1.2 (in Ethiopia) to 4.6 (in Viet Nam). 5 The higher global disease burden 83 
in men—estimated to be 1.8 times higher than in women5—combined with larger detection and 84 
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reporting gaps highlight gender differences in accessing care that may be related to both financial 85 
barriers and stigma.11  The differences also suggest that male-friendly strategies to improve access to 86 
and use of health services are required.12   87 
 88 
Why haven’t we made more progress over the last quarter century? 89 
The lack of progress against TB over the last 25 years has resulted from a mix of political, societal, 90 
scientific, and strategic shortcomings. These include health system frailties; lack of investment in control 91 
efforts, and in research towards developing new medical tools; reliance on simplified, one-size-fits-all 92 
approaches that fail to meet the different needs of individual patients; biological factors, such as HIV co-93 
infection and the spread of drug resistance; and the huge and persistent reservoir of latent TB infection 94 
are all to blame.  Moreover, TB is also ‘a disease of the shadows,’ disproportionately affecting those 95 
communities with the least powerful constituencies to effect change.   96 
 97 
Lack of investment and political will  -Deaths from TB fell rapidly in western Europe and the United 98 
States as living standards improved.  The combination of a decline in TB cases in high-income countries 99 
and the lack of a powerful civil society voice in high-burden countries has undermined efforts to garner 100 
the same political support or domestic  investment as for other diseases.  Failure to appreciate the 101 
profound negative economic impact of the epidemic and advocate for increased donor financing in high-102 
burden, low-income countries has hampered efforts. In many of the highest burden countries, chronic 103 
under-funding and lack of political will have profoundly disabled TB programs,  and also explain why, 40 104 
years after the Alma Ata Declaration,13 half the world’s population still lacks access to comprehensive 105 
health care services.   106 
 107 
Under-investment in TB research and development – Funding for TB R&D has been stagnant for many 108 
years, despite that TB remains a major global health threat.3 A reflection of this under-investment is the 109 
continued reliance  upon tools such as smear microscopy and the BCG vaccine developed nearly a 110 
century ago.14  While global funding for TB research received more funding in 2018 than ever before 111 
($772 million), the pace at which scientific discovery progresses has been greatly hindered by lack of 112 
sufficient funding dedicated to research  priorities that have been defined ad nauseam. 15-17 113 
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Broken care cascades and poor quality of care - Turning the tide on TB requires early, accurate case 114 
detection together with the rapid initiation of and adherence to effective treatment that prevents Mtb 115 
transmission, especially in high-burden countries.  To achieve this, national TB programs in such settings 116 
must first invest to ensure that all patients with TB seeking care have access to TB diagnostics and 117 
treatments.  Unfortunately,TB care is frequently delivered with little attention to patient needs and 118 
preferences, poorly coordinated with other services, and undermined by lack of access to essential 119 
services.18 A recent assessment of patient pathways in 13 countries accounting for 92% of the world’s 120 
missed TB cases revealed that even among people who actively sought care, fewer than one-third 121 
sought care at a facility that had the capacity to diagnose and/or treat people with TB.18-21 Referral 122 
systems to access diagnostic technologies also were limited. These findings confirm those of numerous 123 
other studies from various settings demonstrating the many programmatic and financial barriers22,23 124 
that prevent people with TB from accessing healthcare.24  Furthermore, they highlight how it is critical to 125 
align the availability of services to where people seek care. 126 
 127 
Not only is access highly variable, so too is the quality of TB care in many high-burden countries. 128 
Although the DOTS strategy emphasized the importance of quality-assured drugs and diagnostics, it 129 
neglected to ensure prioritizing the quality of TB care.  The Lancet Global Health Commission on High-130 
Quality Health Systems (HQSS) recently highlighted that the vast majority of TB  deaths result from poor 131 
quality care..25. As Figure 1 demonstrates, the care  quality is undermined by chronic under-funding, 132 
limited access to new tools, and inadequate implementation of policies.   133 
Numerous studies have highlighted substantial gaps in the TB care continuum for all forms of TB cases: 134 
active disease, DR-TB, latent infection, and childhood TB.26-30 For patients with multidrug-resistant TB 135 
(MDR-TB), only 14% completed treatment, and 11% remained disease-free at one year. A similar study 136 
in South Africa found that only 82% of 532,005 TB cases were diagnosed, and less than 54% of drug-137 
susceptible TB cases completed treatment.29 Of those with rifampicin-resistant TB, only 22% completed 138 
treatment (Appendix Figure xx). Simulated patient studies in three countries show that most primary 139 
care providers are unable to diagnose TB and referral linkages to the National TB Program (NTP) are 140 
weak. In India, China and Kenya, only 28% to 45% of simulation patients were correctly managed by 141 
primary care providers.31-33 142 
Simply put, the current global capacity to diagnose, link to care, treat, and cure TB patients is woefully 143 
inadequate for the massive burden of disease that exists. The public health implications, as well as the 144 
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poor clinical and financial implications34 for patients, are self-evident. Substantially reducing TB 145 
mortality and incidence will require significantly increasing both the coverage and the quality of TB 146 
services across the entire care continuum.   147 
Failures to optimize private sector engagement   Of the 3.6 million unreognized or “missing” TB patients 148 
in 2017, 63% of them are in six countries where primary care is dominated by private providers and 149 
>67% of initial care-seeking is in the private sector (Table 3). However, in these countries, private 150 
provider notifications are just 18% of total TB notifications and 9% of estimated TB incidence. Based on 151 
data from TB prevalence surveys and private sector drug sales,35 a considerable proportion of TB 152 
patients are treated in the private sector, with largely unknown levels of quality and patient outcomes. . 153 
Given the dominance of private health care in countries with the largest share of “missing” TB patients, 154 
to meet national and indeed global TB goals, private providers must be engaged to provide high-quality, 155 
patient-centered care on a scale equal to their role in primary care. 156 
 157 
Modeling studies also suggest that untreated or poorly-treated patients in the private sector are a major 158 
source of Mtb transmission.36 This is due to delay in diagnosis and treatment initiation among private 159 
patients, as well as recurrent TB among private patients who were inadequately treated. Therefore, 160 
improving the diagnosis and treatment of patients seeking care in private facilities is an opportunity to 161 
rapidly reduce TB transmission. Engaging private providers can also reduce unnecessary morbidity and 162 
mortality caused by inappropriate treatment, drug resistance caused by undetected MDR TB and 163 
incomplete treatment, and catastrophic expenditures and impoverishment.  164 
 165 
Failure to target resources at hot spots and high risk populations - Global and regional data camouflage 166 
localities where the TB epidemic continues to grow unabated.  Many different micro-epidemics exist, 167 
and the risk of both acquiring and dying of TB are unevenly distributed across society. Even adjacent 168 
neighborhoods may have markedly different TB prevalences, as recent analysis from Chennai, India, 169 
illustrates.37 Such regional variations reflect social and environmental determinants, which include living 170 
in densely populated areas38-40 and working in occupations, such as health care or mining, that increase 171 
the risk for TB.41-43 Turning the tide on TB requires early, accurate case detection together with rapid 172 
initiation of and adherence to effective treatment (both preventive and curative) that prevents 173 
transmission.  To achieve this, national TB programs in high-burden regions must scale up active case 174 
finding strategies for those people and populations at the highest risk, rather than relying on passive 175 
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case finding alone.  Unfortunately, active case finding strategies, even in the highest risk populations, 176 
are not widely implemented because of cost concerns and lack of research consensus on what best 177 
practices should include.44 178 
 179 
Neglecting to implement TB  prevention strategies - Ending TB as a disease of public health significance 180 
must entail a comprehensive, cogent prevention agenda.  Because the human reservoir of M. 181 
tuberculosis infection is enormous,45 overwhelmingly asymptomatic, and long-lived,  identifying 182 
individuals who are at highest risk of progression to disease, who would thus benefit the most from 183 
preventive therapy, is crucial.The benefits of preventive TB therapy have been known for more than 60 184 
years. Pioneering studies in the 1950s–1960s provided overwhelming evidence of the efficacy of 185 
isoniazid  in preventing active TB in children,46  Alaskan Native populations, residents of congregate 186 
living facilities such as mental hospitals, and household contacts of TB patients. 47 Subsequent work has 187 
further documented the benefits of  preventive therapy for individuals with evidence of recent infection, 188 
those with radiographic evidence of prior untreated TB, 48people with HIV infection,49 recipients of 189 
immunosuppressive therapy such as TNF-alpha inhibitors,50 and other immunocompromised 190 
individuals.51  191 
 192 
Large population-based studies of TB preventive therapy and mathematical models both suggest that 193 
preventive treatment of TB infection—as part of a comprehensive approach that includes active case-194 
finding and prompt, effective treatment—can sufficiently reduce population-level transmission to 195 
interrupt the cycle of infection, illness, and death.52,53  Unfortunately, despite abundant evidence of its 196 
efficacy, the use of preventive therapy globally has been limited,54 as TB control programs in LMICs have 197 
focused almost exclusively on detection and treatment of individuals with active TB disease.   198 
 199 
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The problem of drug-resistant TB - Among the 558,000 individuals currently estimated to develop 200 
rifampicin-resistant (RR-TB) each year, most are thought to be infected with multidrug-resistant TB 201 
(MDR-TB, resistance to both rifampicin and isoniazid).55 Despite this large burden, only a quarter of the 202 
estimated number of individuals with MDR/RR-TB were diagnosed and notified in 2017.5  The remainder 203 
either form part of the ‘missing millions’ or were placed on largely ineffective first-line treatment in the 204 
absence of a drug-resistant TB diagnosis. Among those diagnosed, 87% were reported to have been 205 
enrolled on treatment, with only 55% of these successfully treated. This simple cascade leaves only 12% 206 
of the global MDR/RR-TB burden successfully treated.  While there are significant variations in the 207 
prevalence of DR-TB between countries, MDR-TB prevalence can vary by a factor of 10 at the sub-district 208 
level and even more from one health centre to the next. 56,57  The largest number of DR TB cases are in 209 
India (which, along with other high burden countries, has witnessed the emergence of so-called ‘totally 210 
drug-resistant’ strains)58 and China (where one-quarter of all active TB disease cases are resistant to 211 
either isoniazid or rifampicin).59 Importantly, increasing evidence demonstrates that the majority of DR 212 
TB cases reflect transmission rather than initial acquisition.60-62  Thus, a high priority for curbing DR TB is 213 
to interrupt DR TB transmission through early diagnosis and prompt initiation of effective treatment.63 In 214 
parallel, an urgent need exists to develop and trial preventive treatment strategies that are effective 215 
against DR-TB. 216 
 217 
Addressing social determinants - Fundamentally, TB is a disease of poverty.64-67 Most often it causes 218 
substantial losses in productivity for already poor individuals (3-4 months of work) and families (30% of 219 
yearly household earnings).68 Social determinants that contribute to TB risk are linked both directly and 220 
indirectly to social and economic vulnerabilities.65 Surveys in seven countries demonstrate that patients 221 
who develop TB often face catastrophic costs (>20% of household income) just to access care to 222 
diagnose and treat their TB.22,23,69-72 In Viet Nam, for example, 63% of TB-affected households 223 
experienced catastrophic costs, 38% took out loans or sold assets (so-called “dissavings”), and 27% 224 
reported serious financial burdens related to TB-related costs.73 Significant social and economic burdens 225 
make TB patients less likely to present for care, complete TB testing, and initiate and adhere to 226 
treatment,66,74 leading to increased Mtb transmission, morbidity, and mortality.75-81 The financial 227 
impacts of TB disease are significant and long lasting; as we highlight in Panel 3, individuals suffering 228 
from TB in rural India experienced profound financial hardship even seven years after completing TB 229 
treatment. 230 
 231 
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As history demonstrates, the global TB epidemic is not homogenous, characterized by a gradual decline 232 
in incidence.  Rather it is a heterogeneous collection of micro-epidemics in which transmission in each 233 
setting is driven by different catalysts,82 from HIV-induced immune defects to inadequate diagnosis and 234 
treatment.83 In settings where increased attention and resources have been devoted to controlling TB 235 
(for example, New York City,84 Alaska,85 and China59), remarkable successes have been achieved. But in 236 
regions where facilitators of transmission have been left unaddressed (incarceration in eastern Europe, 237 
for example), TB has resurged. To prevent the ‘worst of history’ repeating itself, TB control programs 238 
must anticipate and respond to dynamic demographic, environmental, and socio-economic trends, 239 
mapping each micro-epidemic to clearly understand its drivers and how it  is evolving.  In addition, 240 
anticipating the threats of vulnerable aging populations, global plofieration of urban slums  and the 241 
increasing incidence of non-communicable diseases, such as diabetes and chronic long disease, is 242 
essential.  In the Sustainable Development Goal (SDG) era, ending TB must be framed within a broader 243 
health and development agenda.86 This agenda includes understanding that reducing TB mortality and 244 
improving the health system are inextricably linked with ensuring gender equality (SDG 5), improving 245 
working conditions (SDG 8) and urban planning, (SDG 11) and mitigating the impact of air pollution and 246 
food insecurity caused by climate change (SDG 13).   Purely biomedical or public health solutions are not 247 
enough to end the  tuberculosis epidemic;87 economic development and exigent investment in social 248 
policy  strategies  that can  alleviate the drivers of TB disease are also important. 249 
 250 
 251 
Global Leaders have made a strong political commitment to ending the TB epidemic 252 
The High Level Meeting on Tuberculosis at the United Nations (UNHLM) in September, 2018 endorsed 253 
an ambitious and powerful declaration to accelerate progress towards the goals outlined in the End TB 254 
strategy (Panel 1). Taken together, programmatic innovations, new health technologies, sustained global 255 
economic growth, increasing commitment to attaining UHC, and mounting political momentum to 256 
definitively address TB can all contribute to achieving that goal. A long-term political pledge, however, 257 
requires a clearly defined endpoint and a road-map for how to achieve it.  For the purposes of this 258 
Report, the Commission focused primarily on the goals outlined in the HLM declaration and the End TB 259 
Strategy mortality target: a reduction by 90% from the worldwide level in 2015, which was about 24 TB 260 
deaths per 100,000 population per year (including TB deaths in persons living with HIV).  We  recognize 261 
that efforts to reduce TB mortality must occur in tandem with strategies that prevent ongoing 262 
transmission, and lead to reductions in incidence.   However, focusing on mortality rather than incidence 263 
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is motivated by a desire to make the recommendations of the report relevant to a broad audience of 264 
policy-makers and public health practitioners, for whom change in mortality is a more useful metric of 265 
progress than TB incidence. 266 
 267 
The Commission concluded that achieving that goal within a generation and at a feasible cost, is realistic 268 
in many settings, but it will require substantial investment in resources. Countries like Japan,88 China,89,90 269 
and Peru91 have all demonstrated that rapid declines in TB mortality can occur with sufficient political 270 
will and financial investment, and when multisectoral steps to alleviate poverty occurred in tandem with 271 
efforts to reduce TB mortality. If other countries can  replicate the trends in TB mortality decline 272 
achieved in these countries, then a 90% reduction in TB-deaths worldwide within a generation is 273 
possible (Figure 2).  For some high burden countries, however, even sustained investment will be 274 
insufficient; transformative innovations in service delivery and increased investment in new tools is 275 
necessary to end the  epidemic in these settings.  Thus, our commission set out to answer two questions 276 
as the foundation for creating a roadmap for countries to reduce TB mortality: (1)  How should TB high-277 
burden countries and their development partners target their future investments to ensure that ending 278 
TB is achievable? (2) What policy priorities are necessary to ensure that the HLM political declaration 279 
leads to rapid and sustained progress towards ending the epidemic?   280 
 281 
 282 
Report Roadmap 283 
Section 1, of the  report highlights proven strategies to reduce TB mortality in high burden countries.  284 
We focus first on high-priority strategies needed to close gaps in the care continuum, including person-285 
centered approaches to diagnosis and adntreatment, active case-finding approaches to reach high-risk 286 
populations and the urgent need to implement TB prevention interventions.   We emphasize the critical 287 
need for new models of private sector engagement to deliver high-quality care, and innovative ideas to 288 
optimize care for patients with DR TB.  289 
 290 
The challenge TB now presents also has in part resulted from neglecting to identify TB research as an 291 
integral, critical priority during the last quarter century.92 While ending TB with existing tools is possible, 292 
new products are essential to reduce cost, simplify implementation and accelerate progress.  In Section 293 
2, we describe why current funding for TB research and development (R&D) must increase to expedite 294 
transformative innovations in point-of-care diagnostics; safer, less toxic, shorter treatment regimens; 295 
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chemoprevention; and a more effective TB vaccine. The economic rates of return on greater TB R&D 296 
investment are both substantial and invariably beneficial to poor and marginalized communities.93  297 
 298 
Section 3 highlights how effective TB control represents one of the ‘best buys’ in global development, 299 
one that can produce considerablel economic dividends for high-burden countries. We examine the 300 
potential to expand domestic TB financing through increased revenue generation and prioritizing health 301 
care, as well as from more innovative sources, including loans, gains in efficiency, and complementary 302 
non-TB resources. Efforts to end TB within a generation need to differ dramatically from those in the 303 
past. Rather than relying on a global campaign funded and led by foreign donors and focused on specific 304 
interventions, increasingly TB control efforts will require domestic resources and full country 305 
ownership.94  We discuss how foreign donor support can still play a critical role in ‘transitioning’ 306 
countries to full country ownership by targeting resources to address DR-TB, investing in TB R&D, and 307 
strengthening strategies that ensure sustainable domestic funding for TB control efforts.  308 
 309 
Section 4 calls for a new era of accountability and a reinvigorated cadre of political leaders committed to 310 
doing their part to accelerate efforts to end TB worldwide. Heads of States, national TB programs and 311 
even regional and site-level clinics must be held accountable for their performance in contributing to 312 
ending the epidemic.  We advocate for an independent review mechanism to evaluate the performance 313 
of all major global stakeholders engaged in TB programming.  314 
 315 
 316 
 317 
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Section 1: Scaling up proven strategies 318 
Several high-performing countries have demonstrated that substantive declines in TB mortality, while 319 
difficult to achieve, can be reached by using existing tools to scale up evidence-based, best-practice 320 
interventions.  To substantially reduce TB deaths, we must prioritize delivering patient- and family-321 
centered programs to individuals with active TB, while also reaching high-risk populations with TB 322 
screening and preventive services.  This comprehensive, integrated approach requires first focusing 323 
resources to ensure the availability of high quality services to diagnose, treat, and prevent all forms of 324 
TB in both the public and private sectors.  It then requires investing in strategies to find those suffering 325 
from TB in high-risk communities and scaling up preventive interventions in these communities.   326 
Although no one approach fits all countries, we highlight policy priorities that can inform domestic 327 
budget allocations and donor investments in high-burden countries (section 1.1-1.3), and we also 328 
discuss the specific challenges faced by high-burden countries where private sector care is significant 329 
(section 1.4) and where DR-TB is prevalent or emerging (section 1.5).   To complement these 330 
recommendations, we present modeling analysis from three countries with different epidemiologic 331 
profiles – Kenya, India, and Moldova.   332 
 333 
  334 
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1.1 Ensuring delivery of high quality, person-centred services 335 
1.1.1 Defining person-centered care 336 
To respond effectively to people suffering with TB and to reduce delays in their diagnosis, treatment, 337 
and cure, TB services must be person-centered; that is, they must be holistic, individualized, 338 
empowering, and respectful, encouraging informed decision-making and self-determination.95 Given 339 
that TB commonly affects families, and family members of persons with TB are at high risk for 340 
developing TB disease, services must be family-centred96 in addition to person-centred.  Thus a 341 
thorough assessment of care-seeking behavior, TB epidemiology, as well as local demographic and 342 
health system data, is necessary to determine where to prioritize resources and what ‘delivery gaps’97 to 343 
address first.  In all contexts, the first priority must be ensuring universal access to high quality, person-344 
centred TB care for individuals who are already in the health system.   345 
 346 
Unfortunately, in many high-burden settings, health system frailties are inimical to delivery of person-347 
centered TB services: first, individuals with TB often are neither identified nor appropriately evaluated in 348 
a timely manner;98,99 second, once a diagnosis is established, they are not started or supported to 349 
complete treatment that ensures a durable cure. TB services must align with care-seeking behavior to 350 
bring about person-centred care and prevention. Optimizing alignment of services, both in national TB 351 
programmes (NTPs) and in the non-state sector (private providers, nongovernmental organizations, 352 
etc.), can help ensure higher TB cure rates and improve the efficiency of care delivery to ensure greater 353 
equity and control costs.  By redressing inequities in access, improving efficiencies in delivery, and 354 
protecting patients from physical and financial hardships, these interventions are also integral to robust 355 
health systems and to the broader UN Sustainable Development Goal (SDG) agenda.100   356 
 357 
1.1.1.  Re-thinking TB service delivery 358 
As the UNHLM declaration illustrated, there is strong political commitment to promote person-centred 359 
policies.  There are also solid ethical and moral rationales for adopting a people-centered approach to 360 
TB care.  Providing patients with choices about where they access care and giving them ownership over 361 
clinical decisions can have important beneficial clinical consequences, as recent work in Russia 362 
illustrates.  In one study, persons who were lost to follow up in Tomsk, Russia, where alcohol abuse is a 363 
major comorbiditiy with MDR-TB,  were offered alcohol reduction interventions along with nutritional 364 
support, transportation support and a choice of where they would prefer to receive ongoing care 365 
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(inpatient, day hospital or at home). After the intervention, adherence improved from 52% to 81% and 366 
treatment success of 71% was achieved.101  367 
 368 
To be successful, person-centered TB care demand a radical re-thinking of how treatment is delivered.  369 
Unfortunately, many national TB programs have been slow to embrace new models of care, constrained 370 
by limited technical capacity, scarce resources and a myriad competing priorities.  This Commission 371 
stresses that TB programs need to learn to continuously evolve, responsive to changing demographics, 372 
patient preferences and available data.  Differentiated HIV service delivery has demonstrated not only 373 
how service delivery innovations can improve efficieny and effectiveness, but also how communities can 374 
shape and inform systems.  Marked disparities in particular demographic groups, such as the elderly and 375 
working-age men, highlight how the one-size-fits-all is untenable.   The case for implementing 376 
responsive models of person-centered care that can reduce suffering and end TB within a generation is 377 
clear.95 378 
 379 
1.1.1 Aligning TB services with care seeking patterns 380 
To realize the vision of sustainable health for all, we must ensure that health systems are fully resourced 381 
so all of those at risk for TB care can access TB diagnostic, curative and preventive services.  Immediate 382 
and incremental steps are are needed to strategically required to ensure that available resoureces are 383 
appropriately allocated, with a longer-term goal of creating optimally integrated, patient-centered 384 
health systems.  To do this requires that TB programs pivot resources so that they align with how and 385 
where people with TB, and those at risk of developing TB, seek care.  Patient pathway analysis (PPAs) 386 
mapping the continuum of care for people with TB, using existing population-based surveys and routine 387 
programmatic data, can enable programs to better understand how well patient care-seeking and TB 388 
service availability align, highlighting system-level obstacles to patients accessing care. This is an 389 
essential step to prioritizing efforts and planning the placement of services to meet patient needs and 390 
preferences. This methodology is well characterized,102 and in 2017, results from five countries 391 
implementing PPAs and two countries implementing care cascades were published.18 These analyses 392 
revealed marked mismatches between diagnostic capability and TB care-seeking behavior, with less than 393 
30% of facilities where TB patients initiate care able to perform sputum smear microscopy and even 394 
fewer having the capacity to conduct an GeneXpert test or refer a sample for GeneXpert testing19.  395 
These results also highlighted the need to prioritize deployment of rapid molecular tests in certain 396 
places and strengthen specimen referral mechanisms in others.   In addition, these PPAs demonstrated 397 
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the importance of facility-level data to ensure efficient, targeted allocation of resources and improving 398 
the primary health care network to find the missing cases.   399 
 400 
In 2016, WHO’s Strategic and Technical Advisory Group for Tuberculosis recommended that all countries 401 
complete PPAs as part of their priority-setting and planning processes.103 Implementation guidelines 402 
have been published. However, to date, fewer than 10 countries have completed subnational PPA or 403 
care cascades.102  404 
 405 
Person-centred care requires evidence-based priority-setting 406 
Robust person-centred prioritization and planning demands a paradigm shift in how data is collated and 407 
translated.  Currently, myriad data collection requirements often leave NTPs with numerous data points 408 
that are disjointed, overwhelming, and difficult to apply to decision-making.  Furthermore, in most 409 
settings planning efforts have primarily used epidemiological data to inform resource allocation, rather 410 
than also considering how and where they should target resources to meet patient preferences. Several 411 
recent evaluations have enhanced our understanding of TB patient care seeking patterns, and health 412 
system TB capacities.  However, few of these data are being routinely incorporated into planning 413 
processes yet.  Unfortunately, evidence generation has been heavily driven by top-down planning rather 414 
than by key programmatic questions from NTPs.  In addition, donor requests for evidence-based plans 415 
are not harmonized or synchronized with country-level planning processes. Consequently, countries can 416 
be locked into perpetual planning cycles without time for implementation and learning, which makes a 417 
robust data consolidation process for each plan nearly impossible.  418 
Designing patient-centered programs will require that data and evidence are consolidated so that gaps 419 
in the care continuum are identified.  It also demands that TB survivors and their advocates play an 420 
integral role in how TB care programs are designed, implemented and evaluated.  A systematic and 421 
uncompromisingly person-centred approach to the use of this data, [Appendix Figure xx and Appendix 422 
Case xx], can enable NTPs to take the steps necessary to overcome the obstacles that prevent people 423 
with TB from reaching health services, not being diagnosed when they do reach a facility, or not being 424 
notified and/or completing treatment. 425 
To support countries in moving toward person-centred planning, the global architecture of TB, including 426 
surveillance, technical assistance, and donor financing, will need to better align with this step-wise, 427 
person-centred approach. Currently, global TB results frameworks do not monitor gaps closed along the 428 
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patient pathway or specific health interventions optimized to the patient experience. To address this, 429 
PPAs need to be routinely deployed as key components of a package of evidence that informs priorities 430 
and donor assistance.   While it follows that realignment of resources with care-seeking behavior should 431 
improve the efficiency of allocating NTP resources, further research is warranted to validate this 432 
assumption.   433 
 434 
1.1.2 Utilize network optimization and big data analytics to ensure all patients have access to services 435 
Network optimization is one strategy that can be utilized in high-burden countries to ensure that  436 
patients presenting with TB symptoms, many of whom drop out of the TB patient pathway during the 437 
‘diagnostic phase’104, have access to rapid and accurate diagnostic services.  Borrowing analytic 438 
approaches from manufacturing industries, network optimization seeks to solve how to ensure the 439 
selection of the best network configuration from available alternatives based on selected criteria and 440 
subject to constraints.  Applied to TB diagnostic services, it can help balance the need to increase access 441 
to diagnostic services for those most in need while ensuring cost efficiency and feasibility , informing 442 
instrument placement, sample transportation, referral mechanisms, staffing and geographical 443 
prioritization.  Furthermore, by integrating data from other diagnostic tools, e.g. chest radiography and 444 
HIV testing, and other disease programs, e.g. HIV care and treatment services, network optimization can 445 
enable more precise resource utilization across health sectors and programs.   446 
 447 
One example of this approach comes from Lesotho, where diagnostic network mapping was used to 448 
analyze the NTP’s testing and care cascade and inform procurement decisions. Despite a high unmet 449 
need, less than half of GeneXpert testing capacity was being used in 19 of 25 sites where it was 450 
available. Initially the NTP planned to procure and deploy additional instruments within the network. 451 
However, an analysis found that network capacity could be better optimized by improving referral flows 452 
and adjusting where the placement of existing instruments should be. The analysis also identified a 453 
“sweet spot” where patient demand would make it most worthwhile to place point-of-care diagnostics.   454 
The analysis led to recommendations that 62% of the country’s GeneXpert instruments be re-allocated 455 
for maximal impact.  Referral flows between and across district borders were also adjusted to improve 456 
efficient use of GeneXpert instruments, obviating the need to purchase additional instruments.    457 
 458 
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In the near future, big data aggregated from routine Ministry of Health reports, donor-agency operating 459 
plans, private health systems, and social media, as well as other sectors of government, will help 460 
transform the efficiency of TB programs, enabling targeted scale up of services and providing 461 
unprecedented situational awareness and analytic capability to Ministers of Health and NTP managers.  462 
At present, examples of aggregated data being employed to enhance the delivery of person-centred 463 
programs are scarce in resource-limited settings.    However, integrated data platforms, in combination 464 
with simulation technology, could enable NTPs to create detailed real-time models of the TB case 465 
continuum, incorporating variability in patient care-seeking behaviors, diagnostic capacities, gaps in 466 
linkages and health care costs. In the future, such data systems could provide user-friendly ‘dashboards’ 467 
at each level of the health system, with a single interface for both static and real-time analysis of 468 
complex systems, enabling NTPs to predict changes in patient-demand, anticipate stock-outs, determine 469 
utilization of diagnostic and treatment assets and, ultimately, improve patient care.  Such use of 470 
aggregated, ‘big data’ sources will demand specialized equipment, interoperability standards, coherent 471 
data collection and analysis systems, as well as regulatory oversight.105  However, these approaches are 472 
being successfully applied to address other complex health system problems in the US106,107  and 473 
elsewhere.108 Thus, they couldbe successfully employed to help close delivery gaps for TB programmes 474 
as well. 475 
 476 
1.1.3 Improving quality management to ensure high quality service delivery 477 
In addition to PPA and network design analyses to ensure access to services for all patients presenting 478 
with TB, we must improve the quality of care that patients receive.  Unfortunately, cascade of care 479 
analyses show large gaps in the quality of care for both adults and children, and for both drug-480 
susceptible and DR TB in many high-burden countries.  Simulated patient studies in India, Kenya, South 481 
Africa and China26,28,29 have all demonstrated that the quality of TB care is poor. In a study in China, for 482 
example, health care providers failed to correctly manage the ‘mystery-shopper’ TB patients 59% of the 483 
time.33  In an Indian study, only 21% of practitioners correctly managed TB when presented with a text-484 
book simulated patient. 32    485 
 486 
Traditionally, programmatic impacts and outcomes have been defined primarily by epidemiological 487 
measures. Such a focus, however, overlooks that outcomes tied to improving quality by closing gaps 488 
along the care cascade are more relevant operationally and can accelerate progress. Quality 489 
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management (QM) tools can help front-line providers and NTP managers address those gaps to improve 490 
care quality as well as address the drivers of ongoing TB transmission. 109 491 
 492 
Implementing quality improvement: lessons learned from tackling HIV 493 
Over the past few decades, HIV programs in sub-Saharan Africa, the Caribbean, and Asia have 494 
implemented QM programs to optimize the use of limited resources available from governments and 495 
donor agencies.110 The basic elements of quality management include a formal QM plan, a technical 496 
working group or committee, a set of performance measures, expectations for implementing quality 497 
improvement (QI) activities, staff capacity building, and patient/community involvement. These 498 
elements are necessary to achieve sustainability in the face of expected staff turnover and 499 
environmental changes that affect the stability of healthcare organizations and the workforce. By 500 
leveraging a four-step continuous cycle of improvement (‘plan-do-check-act,’ or PDCA), these programs 501 
have driven substantive change by developing local solutions to improve the quality of HIV/AIDS care.  502 
Improvements have been demonstrated across different facets of care, including treatment 503 
adherence,111 reducing mother-to-child transmission of HIV,112 pediatric services,113 enhancing fidelity to 504 
treatment guidelines,114 and strengthening the clinical capacity of front-line providers.115 505 
 506 
Similar approaches can be used to improve the quality of care for patients with TB, while also enabling 507 
increased levels of accountability at all levels of NTPs. (Appendix Case studies xx,yy and zz provide 508 
examples from the public and private sector, at facility and regional level, of how QI approaches have 509 
been deployed to improve TB outcomes).   510 
 511 
Using the cascade of care as an organizing framework, NTPs can measure quality at the facility-level 512 
using a set of indicators that represent key steps in the care cascade or that reflect the International 513 
Standards of TB Care116 (Appendix Table xx). National reporting of these quality indicators can help NTPs 514 
identify low-performing facilities that may require more support or resources. Furthermore, health 515 
facilities can use the tools of root cause analysis to identify specific barriers and generate ideas for 516 
addressing them.  517 
 518 
However, as pointed out by the Lancet Global Health Commission on High Quality Health Systems, 519 
improving quality will require system-wide action that goes beyond facility-based QI efforts.25  These 520 
actions include better governance for quality; adopting competency-based clinical education and 521 
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training in ethics and respectful care; and creating demand for quality in the population to empower 522 
people so they can hold systems accountable and actively seek high-quality care. 523 
 524 
Implications for national and global stakeholders in implementing a quality management program 525 
Quality management programs must become part of NTPs and ideally integrated into existing national 526 
quality management programs.  Ensuring that NTP managers and their teams have access to this 527 
expertise will facilitate the development of ways to measure and improve quality in their NTP. 528 
Nonetheless, a culture change in how TB data are used to improve care must occur at every level of the 529 
health system, including greater accountability of local TB clinics to patients they serve.  Globally, a 530 
quality management program that embraces improvement methodologies can be a powerful lever to 531 
improve donor-recipient accountability and enhance donor efficiency.  WHO plays a crucial role in 532 
supporting a quality management agenda and creating a global culture that supports QI and accelerates 533 
dissemination of learning through peer exchange.  Linking donor support to quality indicators could also 534 
improve efficiencies in donor financing and enhance transparency. 535 
 536 
1.1.4 Assessing the impact of strategies to deliver high-quality, person-centered services 537 
Together, the strategies described in this section share the common objective of accurately diagnosing 538 
TB as early as possible: they reflect ways of realising the maximum potential impact of a system of TB 539 
services that is contingent on cases presenting for care. What are the potential epidemiological 540 
implications of these measures? Modelling analysis, commissioned for this report, casts some light on 541 
the potential value of these and other measures in three different country settings, each with distinct 542 
challenges in TB control: India (with a large private sector); Kenya (with HIV confection); and Moldova 543 
(with a high burden of MDR TB). The full analysis is provided in (Vesga Gaviria et al, in press, 2018). 544 
Figure 3 Illustrates the example of Kenya: in this setting, patient pathway analysis has already identified 545 
the lack of diagnostic facilities as a key challenge.20 The figure shows the potential impact of measures 546 
that could increase the probability of diagnosis per provider visit to 90%: the impact is to reduce 547 
cumulative TB cases from 2018 – 2045 by 25% (95% credible intervals 11-39%), and cumulative TB 548 
mortality over this time by 38% (95% CrI 17 – 50%). As described in this section, such measures are not 549 
limited to diagnostic tools: they also involve network optimisation, correcting misalignments of TB 550 
services; and other such measures to maximise the effective uptake of rapid, accurate diagnostics.  As 551 
the modelling illustrates, these measures are necessary but insufficient to end TB.  However, in concert 552 
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with the other strategies outlined in section 1, they can enable countries to make substantial progress 553 
towards ending the epidemic. 554 
 555 
1.2 Prioritized active case finding 556 
Besides targeting resources and analyses to ensure high-quality, person-centred care for those 557 
individuals with TB disease that present, another high priority is finding persons with TB, especially 558 
among high-risk populations, who have not yet presented for care.  Strategies to find these “missing 559 
persons” must occur together with scaling up access to preventive interventions.  These two 560 
strategies—active case finding and prevention– must be programmatically inseparable and not divorced 561 
by budget allocation decisions.   While active case finding (ACF) mainly seeks early detection of and 562 
prompt treatment for people with active TB, thereby reducing mortality, morbidity, patient costs, and 563 
ongoing transmission, it also aims to identify people eligible for treatment of latent TB infection.117 In 564 
this section we discuss ACF; in Section 1.3 we highlight the importance of prevention interventions.    565 
1.2.1 ACF: Closing the ‘know-do’ gap 566 
Prevalence surveys in high-burden countries118-120 provide abundant evidence that despite scaling up 567 
and decentralizing TB diagnosis and treatment services, undetected TB cases loom large, especially for 568 
high-risk groups.121-124  Unfortunately, most high-burden countries have not widely implemented 569 
strategies to find these individuals because these countries lack funding, political will, and scientific 570 
consensus.125-127 As a result, the impact of ACF strategies on TB epidemiology in high-burden settings is 571 
limited; only a few  studies have been published, with mixed results.126-129   Nonetheless, recent clinical 572 
research,130 mathematical modeling131,132, and considerable programmatic experience132,133 suggest that 573 
these strategies can be taken to scale.  In the  Russian Federation in 2015, for example, almost half of 574 
the TB burden was detected by actively screening 68% of the prison population.  In Brazil TB screening of 575 
the prison population yielded 6021 new cases, 8% of the total national burden in 2015.134   576 
 577 
While implementing ACF requires a systematic approach, ministries of health and their partners also 578 
need to consider how to scale up targeted ACF interventions. Important considerations include setting 579 
clear goals and objectives based on a thorough assessment of the situation; identifying and prioritizing 580 
risk groups; and choosing simple algorithms and accurate, effective technologies. 133,135  In addition, 581 
consideration should be given to using best practices to disseminate innovations;97,136 establishing and 582 
using networks for change; actively engaging the community; and ensuring strong leadership and 583 
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governance to guarantee the success of ACF activities.  Linking ACF strategies to accountability 584 
frameworks and funding predicated on meeting case-finding targets may also play a role.    585 
 586 
1.2.2 Prioritizing high risk groups 587 
Several groups with diseases or exposures that put them at high risk for TB should always be 588 
systematically screened for TB (see Appendix Table xx).  Among them, household contacts must always  589 
be a programmatic priority, given the strength of evidence demonstrating the impact of strategies 590 
targeted to them.137  The importance of a family-centered approach – and recognition that TB is a 591 
disease that affects families, as much as it affects individuals – has  important implications for ACF, 592 
insofar as NTPs need to understand the family, not the individual, as the ‘unit of intervention.’ 593 
 594 
Other risk groups may warrant targeted screening programs based on epidemiology, health system 595 
capacity, availability of resources, and feasibility. Given higher rates of TB in men compared to women in 596 
almost all high-risk groups,12 male-friendly strategies, such as workplace interventions should be 597 
employed where feasible.  In preparing ACF scale-up strategies, the risk of discrimination and 598 
stigmatization should be carefully addressed.  In addition, the legal status of migrants, with regard to 599 
both access to health services and risk of expatriation in case of TB diagnosis,  needs to be considered.138  600 
Engaging with civil society groups to better understand the expectations and concerns of high-risk 601 
groups when planning and implementing TB screening activities is critical to their success.  602 
 603 
Opportunities for integrating ACF with other essential services for these populations should be exploited 604 
where possible, especially when  high-risk groups are already served by vertical, facility-based 605 
programs139 or private providers140 and where ACF activities can be aligned with other health promotion 606 
activities.141  For some high-risk populations—such as people living in slums, the homeless —innovative, 607 
multipronged case-finding strategies, leveraging m-health technologies, and incorporating social 608 
protection strategies, may be necessary to maximize yield and rationalize costs140,142 609 
 610 
1. 2.3 Anticipating costs and using planning tools 611 
Scaling up ACF strategies will require substantial additional resources. The cost of screening can be high 612 
per case identified,143-145 especially when compared with other health promotion interventions.146 613 
Nonetheless, as highlighted in Section 3, evidence on the cost-effectiveness and benefits of expanded 614 
financing for ACF suggests that such investments will yield a high return. Modelling performed as part of 615 
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the South African government’s investment case for TB (Figure 7) also illustrates that the declines in TB 616 
transmission resulting from higher case detection and optimal treatment will be highly cost-effective if 617 
major and durable reductions in TB incidence and prevalence are achieved.  Other modeling studies that 618 
include the benefits from reduced rates of transmission also confirm that even where active screening 619 
costs are high, ACF strategies still can be highly cost-effective.131,145  620 
 621 
Planning tools, such as the WHO’s online ScreenTB tool,147 can help NTPs plan their case-finding 622 
activities and prioritize risk groups for screening by modeling the potential case yields and costs of 623 
different screening approaches. The ScreenTB tool allows the user to select risk groups of interest and 624 
compare estimates of the yield of screening (including true-positive and false-positive cases found), the 625 
total costs, and the cost per case detected across the selected risk groups and across different screening 626 
algorithms.   627 
 628 
1.2.4 Leveraging technology to improve the efficiency of case-finding strategies 629 
The tools used to screen for and diagnose TB are crucial in determining the efficacy of systematic 630 
screening.  A rapid triage test that would enable active screening in the community would be a more 631 
efficient, person-centered approach to case-finding than current approaches and warrants substantial 632 
investment (Appendix Panel xx).  Mobile, automated, digital chest radiography units, to detect lung 633 
lesions in people who are relatively asymptomatic148,149, may also help detect many more patients with 634 
TB than is possible through passive case finding or self-reporting.  While data are sparse,150 computer 635 
aided detection tools, used in concert with digital radiography,  could substantially increase diagnostic 636 
sensitivity while also saving money.  Clearly, this technology will also enhance sensitivity for detecting 637 
other pathology, in addition to pulmonary TB, underscoring the importance of incorporating ACF in the 638 
setting of comprehensive primary care services. 639 
 640 
In addition to new diagnostic technologies, better use of available data—aggregated and anonymized, 641 
and collected from a variety of sources, including social media, pharmacies,35 and the private sector—642 
have the potential to enhance both the precision and efficiency of ACF interventions.  Already, social 643 
network data, mobile phone records, and spatial data have been combined to improve HIV testing rates 644 
in Uganda151  and to  show that imported malaria contributes significantly to disease burden in urban 645 
centers in Kenya.152  Notably, the impact of these additional data to address TB ACF efforts will be small 646 
unless they can be captured and integrated into existing data systems.   647 
THE LANCET COMMISSION ON TUBERCULOSIS 
24 
 
 648 
1.2.6 Finding cases in lower-risk populations 649 
Reaching the general population through ACF should remain a low priority until high-risk populations are 650 
successfully covered. Nonetheless, recognizing that ACF is a high-value intervention, both 651 
epidemiologically and economically, lower-risk populations in high-burden countries should not be 652 
ignored.  The identification of the most effective mix of interventions and strategies that NTPs can use 653 
to detect patients in both high risk and lower risk populations, and the empowerment of NTP managers 654 
to select the most appropriate combination of approaches in their unique settings, are key for success. 655 
Within a country, different provinces or districts might use various methods, depending on population 656 
sociodemographics, civil society engagement, and health system assets.   Selecting appropriate 657 
interventions and strategies hinges on a rigorous, ongoing process of scientific research, knowledge 658 
sharing, and monitoring and evaluation.  659 
 660 
1.2.5 Recognizing that ACF in high-risk populations will not be enough 661 
ACF alone will be insufficient to eliminate TB in high-risk populations. Even if we identify more 662 
individuals with TB in at-risk populations, those patients will return to their high-risk pools where the 663 
prevalence of TB risk factors are high.  A multisectoral approach is essential to ensure that drivers of TB 664 
risk such as malnutrition and air pollution are addressed.  It is also vital that ACF interventions are 665 
programmatically inseparable from interventions targeted at preventing TB disease in those latently 666 
infected and at greatest risk of developing active TB.    Such interventions are discussed in more depth in 667 
the next section. 668 
 669 
  670 
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1.3 Prioritizing TB prevention 671 
As noted in Section 0, TB prevention is a crucial but neglected component of global control of the TB 672 
epidemic.  For the past 50 years, global strategies for controlling TB have focused on passive case 673 
detection and treatment of active disease. However, mathematical modeling shows that this approach 674 
alone, while averting deaths and relieving suffering, will not end TB. Rather, ending TB will require 675 
multiple different preventive interventions to interrupt transmission, treat latent infections, immunize 676 
close contacts, and treat or prevent comorbidities, such as HIV, that increase susceptibility to developing 677 
active TB. Table 4 illustrates some populations that may benefit from prevention interventions.153 While 678 
this subsection focuses primarily on TB preventive therapy (TB PT), TB Infection control in healthcare 679 
facilities and congregate settings such as prisons is also critical to TB prevention efforts: healthcare 680 
centers and hospitals are often hotspots of TB transmission, and instituting environmental control 681 
measures and rigorous administrative and personal protective strategies is likely to reduce the 682 
transmission risk substantially.154  683 
 684 
1.3.1 Targeting preventive therapy 685 
TB preventive therapy (TB PT) likely offers one of the most effective interventions to reduce TB 686 
incidence globally. In addition, by preventing TB and reducing mortality by treating those with latent 687 
infection who are greatest risk of becoming ill, TB PT is a necessary component of a comprehensive 688 
strategy to end the epidemic.  Even improved strategies for diagnosis and treatment will not address the 689 
large reservoir of latently infected people (estimated to be approximately 2 billion globally) who may 690 
develop TB at any point in their lifetimes.45  Clearly targeted TB PT could significantly reduce rates of TB 691 
disease in the highest risk groups. These groups include people with HIV infection; household and other 692 
close contacts of persons with infectious TB; and persons working or living in settings that foster the 693 
transmission of M. tuberculosis, such as congregate living settings, prisons, healthcare facilities,155,156 694 
and underground mines, especially those in which there is silica exposure, which, in itself  greatly 695 
increases risk123,157.  Moreover, the process of providing TB PT will uncover active cases, as candidates 696 
for PT undergo screening to rule out disease before beginning treatment, which identifies previously 697 
undetected cases of TB disease.   698 
 699 
Although the effectiveness of TB PT in preventing active TB disease is well-established,48 public health 700 
programs have prioritized TB case finding and treatment rather than implementing this inexpensive and 701 
highly effective intervention. HIV programs have focused primarily on rolling out lifesaving antiretroviral 702 
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therapy, not least because of compelling evidence of its efficacy as TB prevention intervention.158,159 703 
Recent  studies have shown that TB PT using isoniazid significantly reduces rates of death in people with 704 
both early and advanced HIV infection. 160-162 People with HIV and household contacts of active TB cases 705 
can benefit substantially from TB PT. Globally, modeling studies find that wider uptake of TB PT, coupled 706 
with improved case-finding and treatment, is more important than an effective vaccine for reaching TB 707 
elimination by 2050162, and that household contact evaluations and use of TB PT would avert 99,000-708 
117,00 deaths per year in children <15 years of age.163  This data underscore the importance of a family-709 
centered approach to TB care to ensure that these contacts are routinely screened as part of the routine 710 
management of all persons diagnosed with TB.    711 
 712 
Numerous obstacles have hindered the scale-up of TB PT, and innovative approaches must be taken to 713 
overcome these barriers (Appendix Table xx).153 Improved diagnostic tests to document TB infection, 714 
including point-of-care (POC) tests, would facilitate treatment of infection in persons with an increased 715 
risk of developing TB, such as household contacts, though young (<5 years) child contracts and all people 716 
living with HIV in high-burden areas could potentially be treated without testing.  Prognostic biomarkers 717 
that identify latently infected people who are most likely to progress to active disease would allow more 718 
targeted use in high-risk populations and broader use of PT in lower-risk populations.  Global supplies of 719 
essential drugs such as isoniazid (INH) and newer agents such as rifapentine are unreliable, and stock-720 
outs are frequent; improving the supply chain of inexpensive and quality-assured drugs is therefore 721 
critical. The duration of PT using INH,  now 6-9 months, often results in non-adherence and is leading to 722 
widespread concerns, largely unfounded,164 about TB PT causing drug resistance. Novel short-course 723 
regimens, such as 12 weeks of weekly rifapentine and INH, or a 4-week regimen of daily rifapentine and 724 
INH, could transform prevention efforts, 165-167  reduce the risk of resistance emergence,  while also 725 
saving money and lives. 165,168,169  Nonetheless, rather than waiting for new diagnostics and shorter 726 
courses, this Commission asserts that NTPs should increase access to TP PT now. (While scarce, there 727 
are examples of how NTPs and their partners have successfully implemented TB PT at scale; we highlight 728 
these in cases Appendix  xx and Appendix yy).   729 
 730 
To realize the full impact of preventive therapy, NTPs must devote resources to ensuring that ACF and 731 
TB PT are integrated into existing programs for specific high-risk populations.  Integrating TB screening 732 
and preventive services into care for people living with HIV (PLWH) is particularly important, especially 733 
given extensive, high quality research demonstrating the life-saving benefits of this strategy.160,170 Global 734 
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efforts to provide antiretroviral therapy have now reached 20 million individuals with HIV, but another 735 
17-19 million remain untreated.  Fewer than four million people with HIV have ever received TB PT, 736 
highlighting the opportunity to substantially scale-up this intervention. Failure to scale up TB PT in 737 
people living with HIV has likely caused several million deaths over the past decade.170.   738 
 739 
In collaboration with the Lancet Commission, a team at Imperial College, School of Medicine, London 740 
conducted an analysis to determine the impact of TB PT using isoniazid as currently recommended in 741 
countries with high rates of TB/HIV co-infection.    By increasing TB PT among PLWH in Kenya to 90% 742 
(Figure 4)TB mortality could be reduced by 17% between now and 2045.  In South Africa, a similar 743 
increase in TB PT coverage would lead to an even greater reduction in mortality over the same time 744 
frame.   To achieve this impact, as well as to extend TB PT to other eligible groups recommended by 745 
WHO,171 will require additional investment.  The incremental cost to the TB program of increasing TB PT 746 
in Kenya and South Africa would be relatively modest (estimated to be US$66 million per annum 747 
between 2018 and 2045 to achieve results highlighted in Figure 4), especially when compared to the 748 
economic costs of avoidable deaths resulting from failure to implement this strategy. The efficiency of 749 
that investment can be enhanced by optimal use of health systems data to enable NTPs and their 750 
partners to plan interventions and monitor the impact of prevention strategies.172,173 TB report card 751 
tracking progress on these data at regional and local levels may also help accelerate TB PT scale up 752 
efforts and ensure that NTPs and their partners are more accountable to civil society organizations and 753 
funders.  The success of scale up TB PT efforts will also be contingent on recognition of the importance 754 
of shared responsibility (Appendix Table xx) from across health programs and community stakeholders. 755 
 756 
1.4 Importance of private provider engagement: from acknowledgment to prioritization 757 
In most low- and middle-income countries, private providers are an important source of healthcare for 758 
people of all socioeconomic groups, often offering accessibility and convenience not provided in the 759 
public system. Strictly speaking, “private” is synonymous with “non-state” and includes the for-profit as 760 
well as the non-profit sectors, i.e., non-governmental organizations (NGOs) and faith-based 761 
organizations (FBOs). While most countries could improve their engagement of public and NGO/FBO 762 
providers, engaging for-profit private providers, which is even more important for TB control, has been 763 
much more difficult. In this section, we discuss some reasons for the failure to engage private providers, 764 
recent progress in how they can be engaged on a large scale for TB care, and the critical actions 765 
countries must take to prioritize private provider engagement as part of their TB programs. We highlight 766 
THE LANCET COMMISSION ON TUBERCULOSIS 
28 
 
strategies to enable high quality TB care in the private sector, opportunities for greater syngergy 767 
between NTPs and private providers, and how the extended capability that the private sector provides 768 
can be leveraged to find those people with TB disease that are being missed by current NTP surveillance 769 
efforts. 770 
1.4.1 Making engagement of private providers a priority 771 
The need to engage private providers for TB control has been acknowledged in various global strategies 772 
since the early 1990s.174 Unfortunately, NTPs and their development partners have not focused 773 
sufficiently on engaging private providers in TB, and resources have not been adequate to meaningfully 774 
tackle this issue. Before the most recent funding allocation, the Global Fund to Fight AIDS, Tuberculosis, 775 
and Malaria (GFATM), which provides 56% of international development assistance for TB, had allocated 776 
less than 5% of grant budgets to engage a range of non-NTP providers defined as part of the “public-777 
private mix.”175 Because the GFATM responds to country requests for how its grant funds will be used, 778 
ultimately this small percentage reflects the low priority that countries place on engaging their private 779 
providers. Although data on how much NTPs spend to engage private providers is scant, an example 780 
from India is illustrative: until recently, only 1.5% of the state-level TB expenditure was allocated to 781 
engage NGOs and private providers.176   782 
Failure to engage private providers is often blamed on NTP staff shortages, but clearly the constraints 783 
are much more profound.177 Most health systems in low- and middle-income countries are weak in 784 
areas essential for effective private provider engagement, such as regulatory enforcement, strategic 785 
purchasing, and health information systems.  NTPs often lack basic information on the number of 786 
private providers, their role in TB patient care-seeking, and the drivers of patient and provider 787 
behaviors. Therefore, NTPs find it difficult to engage hundreds and thousands of independent private 788 
providers with widely varying capabilities. For their part, private providers are often wary of engaging 789 
with government programs and, given competitive market dynamics and financial imperatives, unwilling 790 
to adhere to guidelines promoted by NTPs.  791 
Failure to meaningfully engage private providers reflects a strong preference for the public sector 792 
among those who manage TB programs, those who fund them, and those offering technical support. 793 
The TB community has successfully embraced many innovations, including new diagnostics, treatment 794 
tools, and approaches to address TB/HIV and multidrug-resistant TB (DR -TB). These innovations, 795 
however, should be adopted in the private sector without challenging the basic public-sector business 796 
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models. Private provider engagement can succeed at scale only when NTPs acknowledge that they 797 
cannot continue using the current business model (Table 5).  Nonetheless, such engagement must occur 798 
in tandem with strategies that protect patients and their families from catastrophic financial losses that 799 
can arise from accessing care in the private sector.178,179  In working towards ending the TB epidemic in 800 
countries with a large private sector, it will be  essential to protect the interests of poor people by 801 
ensuring that public resources are applied to reduce user fees, while leveraging the private sector to 802 
expand TB diagnostic and treatment coverage. 803 
 804 
1.4.2 Catalyzing progress and new opportunities to engage private providers 805 
Although private provider engagement in TB is far from adequate, considerable experience has accrued 806 
regarding how to successfully engage private providers for TB care.180 Many small, externally supported 807 
pilot projects to engage private providers have been implemented over the years. A study in 2006 808 
reviewed data from 15 projects in 8 countries,181 a systematic review in 2011 considered 45 studies from 809 
22 projects in 12 countries182, and another in 2016 found 78 studies documenting 48 programs in 16 810 
countries.183 Although, most projects have failed to reach significant scale or to be sustained over long 811 
periods. Nevertheless, these projects have generated abundant evidence that engaging private 812 
providers can significantly increase TB case detection and achieve treatment success rates that are at 813 
least as good as those in the public sector. Data on cost-effectiveness, financial protections, delays to 814 
treatment, and reaching the poor is less robust but also available.184  New research continues to add to 815 
our understanding of the functioning of private healthcare markets with respect to TB.31,185,186 816 
More recently, sustained scale-up of private provider engagement has taken place in several key 817 
countries (Figure 5). Bangladesh has sustained a moderate level of private provider engagement for the 818 
past five years, with private notifications reaching 18% of incident cases, while notifications in Myanmar 819 
have declined recently from similar levels. Recently, India, Pakistan, and the Philippines all increased 820 
their engagement of private providers, with private notifications increasing to 9%-13% of incident cases 821 
in 2016. Unfortunately, Indonesia and Nigeria–two countries with substantial numbers of “missing” TB 822 
cases–have made little progress, with private notifications averaging just 4% and 1% of estimated 823 
incidence, respectively. 824 
In Bangladesh, Myanmar, and Pakistan, engagement of large numbers of private primary care providers 825 
has been led by strong non-governmental organizations (NGOs) acting as intermediaries between 826 
providers and the NTPs. These mission-driven NGOs have identified enhancing private provider 827 
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engagement for TB as part of their long-term role and have succeeded in attracting resources from 828 
multiple donors to sustain their work. Some are generalist NGOs, such as BRAC in Bangladesh and Mercy 829 
Corps in Pakistan; others are more focused on TB, such as Damien Foundation in Bangladesh and more 830 
recently Interactive Research and Development in Pakistan; Greenstar in Pakistan and Population 831 
Services International in Myanmar are social marketing organizations that have long engaged private 832 
markets for family planning and other health issues. All these organizations have in common an 833 
understanding of private providers, the ability to operate at scale, strong management systems (for 834 
human resources, information, and logistics), dynamic leadership, an aptitude for adaptation and 835 
innovation, and success in fundraising. 836 
Efforts in Indonesia and the Philippines have focused on private specialists and hospitals rather than 837 
primary care providers. The NTPs have partnered with specialist-led associations (such as the Indonesia 838 
Pulmonologist Society and the Philippines Tuberculosis Society). However, much of the initial care-839 
seeking and TB treatment in these countries are among private primary care providers, and therefore 840 
more effort to engage these providers will be needed. Social health insurance schemes, approaching full 841 
population coverage in both countries, are contracting with an increasing number of private providers 842 
for primary care services. Yet collaboration between the NTP and social health insurance remains quite 843 
limited.15 844 
One of the most exciting developments is the recent political commitment in India to scale-up private 845 
provider engagement nationwide, building on the success of several large demonstration projects 846 
(Appendix Panel xx).16 India’s National Strategic Plan for TB (2017-2020) commits to a massive expansion 847 
of private provider engagement and calls for a six-fold increase in private notifications to two million 848 
patients per year by 2020, which would represent 75% of estimated TB incidence. If India’s plan 849 
succeeds, it will be the first major high-burden country with a dominant private healthcare sector to 850 
align its TB program with the care-seeking patterns of its population. Private notification targets for 851 
Bangladesh, Pakistan, Indonesia, and the Philippines are much more modest: 18-24% of estimated TB 852 
incidence by 2020 (Figure 5). Overall, at least 10 countries have recently prepared PPM Action Plans,17 853 
and the latest round of GFATM funding (2018-2020) includes substantial components for private 854 
provider engagement in several countries.   855 
As successful experiences on private provider engagement accumulate, defined packages of 856 
interventions could be disseminated as templates that could be adapted for rapid scale-up.18  The core 857 
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interventions in such templates include defined activities to engage private providers (including 858 
stakeholder consultation, provider mapping and prioritization, relationship management, facilitating 859 
reporting of TB cases and data, and patient support for adherence); addressing financial and non-860 
financial incentives for private providers, and ensuring private patients have access to quality drugs and 861 
diagnostics according to national protocols. While intervention packages can and have been summarized 862 
in general terms, continued innovation and adaptation should be encouraged.   863 
In addition, legal and regulatory frameworks should be in place to ensure TB notification and quality 864 
services by private providers. Several countries have re-issued laws and regulations requiring providers 865 
to report  cases, sometimes conditioning re-licensing and accreditation to TB notification.19  While 866 
regulatory penalties may have a role to play, countries most successful in engaging private providers 867 
have invested more in enablers (such as call centers to facilitate notification) and incentives (such as 868 
easy access to drugs and diagnostics) while respecting private providers’ interests. Professional societies 869 
can be and have been successfully engaged to help define best practices for TB among private providers. 870 
Looking ahead, new opportunities and developments could enhance private provider engagement for 871 
TB in the coming years. First, success in a country like India could set an example that inspires other 872 
countries. Second, the digital revolution is finally reaching TB.  The use of information and 873 
communication technology (ICT) systems, coupled with call centers, can facilitate the engagement of 874 
private providers and provide digital, case-based information on private TB patients. Third, such ICT 875 
systems can enable additional innovations that further facilitate private provider engagement at scale, 876 
such as digital vouchers for drugs and diagnostics, adherence monitoring technologies, and digital 877 
payment of incentives and enablers to both patients and providers. Fourth, access to new and improved 878 
diagnostic and treatment tools, such as digital chest x-rays and Xpert MTB/RIF®, increased the value to 879 
private providers of engaging with the public sector. Finally, the emergence of social health insurance 880 
schemes for UHC offers an unprecedented platform to engage private providers at scale across all health 881 
conditions and provides an opportunity to improve quality and access of both curative and preventive 882 
TB services  in the private primary sector in countries like Indonesia and Philippines.20,21  883 
 884 
The challenges of optimizing private sector to deliver high TB quality care, while protecting patients 885 
from excessive out-of-pocket expendiure, are considerable.  To be successful these models must  886 
minimize fee-for-service payments that reward quantity over quality and do not promote high value, 887 
low cost interventions, such as TB preventive therapy.  Nonetheless, as part of a broader UHC agenda, 888 
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leveraging private sector services to provide public-financed services may enable extended capability 889 
while aso accommodating the preferences of those  most at risk for, or suffering from TB.187 890 
 891 
1.4.3 Modeling the impact of optimal private sector engagement 892 
Because of the large burden of TB that is managed in the private sector globally, it is essential to assess 893 
the impact of improving private sector engagement.  Modeling commissioned for this report assessed 894 
how greater private sector engagement in a high-burden country like India, where private providers 895 
offer extended capability, could influence TB incidence and mortality.  In such a setting, strategies to 896 
improve quality of private sector care, such as subsidized TB diagnostics, and NTP-funded adherence 897 
support mechanisms for patients accessing care privately, would avert 28% of TB deaths over the next 898 
30 years, saving an additional eight million lives from TB, beyond those lives saved by full 899 
implementation of other evidence-based interventions (Figure 4).  The additional cost of optimized 900 
private sector engagement would involve an annual increase of US$290 million in NTP costs.  While this 901 
strategy alone would not be enough to end the epidemic in India, it has the potential to substantially 902 
reduce the public health threat posed by TB.  Further, enhanced private sector engagement in concert 903 
with other strategies to close gaps in the care cascade, such as targeted ACF interventions, optimization 904 
of diagnostic networks, and improved adherence support strategies, could lead to significant reductions 905 
in TB mortality over the next 30 years.188 906 
 907 
 908 
 909 
  910 
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1.5 Tackling drug resistance 911 
Over the next decade, at least six million people are projected to develop drug-resistant tuberculosis 912 
(DR TB). At current levels of treatment provision and success, most of these people will die from TB, 913 
with many transmitting their DR infections to others before they succumb. By 2050, one-fourth of the 914 
predicted 10 million annual deaths attributable to antimicrobial resistance (AMR) globally are expected 915 
to be due to DR -TB, which will make it the leading cause of AMR-related death and Mtb the most 916 
significant airborne pathogen that is drug-resistant.189  917 
 918 
Given these projections, addressing TB drug resistance is essential both for curtailing the global AMR 919 
crisis and ending TB. Although providing universal drug resistance testing and scaling up access to high-920 
quality, tailored treatment for DR -TB will require substantial funding and commitment, the 921 
consequences of not doing so would be enormous, including massive loss of life and trillions of dollars 922 
spent as multidrug-resistant TB (MDR -TB)  increases dramatically.189  Furthermore, addressing DR -TB 923 
cannot be divorced from scaling up access to diagnosis and treatment of drug-susceptible TB; if we 924 
improve case detection for drug-susceptible TB without a meaningful change in quality and 925 
identification of DR -TB, we will only increase the selection pressure for DR -TB.   926 
 927 
A modelling analysis commissioned for this report demonstrates the impact of ensuring universal access 928 
to DST and second-line therapy in a high DR -TB country such as Moldova.  As highlighted in Figure 4, 929 
optimizing access to DST and increasing treatment success rates would lead to a 43% reduction in TB 930 
mortality and a 73% reduction in incidence over the next 30 years. With adequate investment in tools, 931 
the prospect of definitively addressing the threat of DR -TB within a generation is credible. 932 
  933 
Encouragingly, the rapidly evolving field of DR -TB diagnostics and the increasing availability of new and 934 
repurposed drugs and regimens for treating patients with multidrug-resistant/rifampicine-resistant 935 
(MDR/RR) TB present opportunities to dramatically improve the epidemic response (Appendix Table xx). 936 
Emerging data suggest that in high-burden settings, more than 90% of incident MDR/RR-TB disease 937 
results from direct transmission of already resistant TB bacteria from one person to another.61,62 As a 938 
result, failure to diagnose and effectively treat a significant proportion of individuals with active TB 939 
disease is a major driver of the epidemic. Barriers to diagnosis and treatment scale-up vary across 940 
countries but include 1) the high cost of providing treatment (although data show such costs can 941 
decrease dramatically when more individuals are offered access190); 2) perceived complexity of 942 
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treatment regimens; 3) poor programmatic treatment outcomes in most part due to lengthy and toxic 943 
drug regimens that impose enormous burdens on individuals;; 4) reliance on centralized and specialized 944 
treatment; and 5) lack of political will and commitment.191-194  945 
 946 
Because most DR-TB is caused by direct transmission, early diagnosis and initiation of effective therapy, 947 
combined with effective preventive therapy for close contacts should be key priorities in  preventing DR- 948 
TB195.189 While, reducing the risk of further resistance development, particularly to new TB drugs, is also 949 
of concern, with data suggesting that when TB drugs are used as “last resort options,” resistance is more 950 
likely to emerge196 , policies that ‘protect’ the drugs rather than prioritising improving patient care 951 
through expanded use are neither scientifically sound nor patient-centred. Rather, strategies for 952 
implementing new TB regimens need to take into account the factors that led key first-line drugs to 953 
acquire resistance in the past.  Such factors include varying individual pharmacokinetics, comorbidities 954 
(particularly those that may affect drug absorption, e.g., HIV), poor drug quality, inadequate dosing, 955 
weak supply chains and inadequate prescribing, and selective treatment adherence.197-202 Weak health 956 
systems that offer limited support for patients and their families contribute to many of these factors, 957 
emphasizing the importance of strengthening health systems to help respond to the DR TB epidemic and 958 
provide more patient-centred care.203-205 Because TB drug resistance emerges spontaneously and can be 959 
selected for during treatment,206 using standard combination regimens in patients with undiagnosed 960 
drug resistance likely will contribute to further resistance acquisition, in addition to poor patient 961 
outcomes.207-212 Robust stewardship mechanisms, especially in the private sector, such as that recently 962 
described for a large private hospital in India, are crucial in this regard.213 963 
 964 
1.5.1 Increasing universal access to drug susceptibility testing 965 
Given the clear requirements to find and treat all individuals with DR -TB, and to prevent the emergence 966 
of further resistance, universal drug sensitivity testing (DST) (to rifampicin as a minimum) with access to 967 
second-line treatment is a key recommendation of this Commission.  Prompt use of molecular DST for 968 
patients failing first line therapy should also be implemented to obviate the practice of standardized re-969 
treatment with a regimen that only includes one additional drug and is highly likely to contribute to 970 
resistance amplification, in addition to poor patient outcomes.   971 
 972 
Until relatively recently, diagnosis of DR -TB relied on TB culture, with consequent long delays and the 973 
need for specialised laboratories.214 Because DR -TB results from the presence of resistance-conferring 974 
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mutations in the bacterial genome, newer tests, such as the Xpert MTB/RIF test215 and line probe 975 
assays216, rely on identifying mutations known to infer drug resistance. These more rapid tests have 976 
shortened the time required to receive results from months to hours,215,217 consequently reducing how 977 
long it takes to initiate treatment across a range of settings,218,219 and they are being used at scale in 978 
some countries (Appendix Panel xx). Newer versions of these and related tests, including whole genome 979 
sequencing, are expected to expand the range of drugs that can be tested and reduce reliance on 980 
specialised laboratories.220-222 A pipeline of candidate point-of-care diagnostics, implemented at the 981 
same time as an initial health care visit, have the potential to dramatically improve case detection and 982 
reduce losses along complicated diagnostic and care cascades.5,223,224 983 
 984 
1.5.2 Improving DR -TB treatment 985 
The high MDR/RR-TB burden and poor patient outcomes highlight the dire need for safe and effective, 986 
less toxic, shorter,  and less costly treatment regimens for MDR/RR-TB.55,225-228 Encouragingly, two new 987 
TB drugs (bedaquiline and delamanid) are now available for use in MDR/RR TB treatment.229-231 These 988 
drugs, along with drugs repurposed for TB (including linezolid and clofazimine) and pretomanid (a 989 
similar drug to delamanid), are included in a range of new, shorter, all-oral regimens currently being 990 
tested in clinical trials for MDR/RR TB treatment.232 Results from most of these trials, however, are not 991 
expected for several years.233 In the meantime, these new and repurposed drugs have been increasingly 992 
used programmatically. Data from South Africa suggest dramatic improvements in mortality and 993 
reductions in treatment failure among more than 3,000 patients treated with bedaquiline to date 994 
(Appendix Panel xx).234 As a direct result, South Africa recently announced the implementation of an 995 
injectable-free, bedaquiline-containing treatment for all RR-TB pateints.235 996 
 997 
The South African data, complemented by a large individual MDR-TB patient-level meta-analysis, have 998 
contributed to new WHO guidance prioritising the use of bedaquiline and linezolid for MDR-TB 999 
treatment.236  To date, there is insufficient data to support similar prioritisation for delamanid. 1000 
Increasing the use of these new and repurposed drugs would remove reliance on some of the more toxic 1001 
and less effective drugs, including the second-line injectable agents, which are associated with 1002 
irreversible hearing loss in up to 50% of individuals who receive them.237  It also would help relieve the 1003 
burden on the health care system to deliver the daily injections.238 However, to date, uptake of new 1004 
drugs based on previous WHO guidance has been disappointingly limited, despite a US Agency for 1005 
International Development (USAID)/ Janssen Pharmaceuticals (Beerse, Belgium) donation program in 1006 
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many countries.239  Barriers include drug costs, difficulties in individual country regulatory approval and 1007 
drug procurement,  and lack of high level national government support.240 Overcoming these barriers is 1008 
essential moving forward.  As highlighted earlier, TB programs also need to be continuously evolving, to 1009 
ensure that national guidelines and clinical practice reflects the best available evidence.  Civil society 1010 
organizations have a vital role to play ensuring that this is the case. 1011 
 1012 
Additionally, a more individualized approach to DR- TB treatment—one that encompasses access to all 1013 
second-line drugs and is guided by more extensive DST through whole genome sequencing—would 1014 
enable individuals with DR -TB to receive the best chance of cure, while limiting both the unnecessary 1015 
use of toxic drugs and resistance amplification.241 Such an approach would need to be supported by 1016 
implementation research to guide its integration into existing TB programmes and the health system as 1017 
a whole, in addition to pharmacovigilance systems.233,242,243  While full treatment individualisation may 1018 
not be feasible in all settings, more stratified approaches that takes into account local drug resistance 1019 
profiles are potentially feasible.244 1020 
 1021 
 1022 
Given the arduous nature of current TB treatment regimens as well as socioeconomic challenges, many 1023 
patients withdraw from treatment before completing the full course: globally reported as 15% in the 1024 
2014 cohort, and ranging between 1% and 56% in individual studies, with a tendency to increase as 1025 
more patients are treated in a particular setting.55,245 These data emphasize the need for more patient- 1026 
and household-centered approaches that ensure health systems are optimally aligned with the needs of 1027 
the populations affected by DR -TB.  While the emphasis has been on improving adherence and reducing 1028 
catastrophic costs, a person-centered model of care also includes ensuring that people with possible DR 1029 
-TB (and those supporting them) are fully informed about, and included in, therapeutic decisions. At 1030 
their heart, such models must tackle active discrimination within the health system as well as in other 1031 
sectors. Person-centered care also includes providing treatment closer to where patients live and 1032 
initially seek care, i.e., community-based and decentralised as much as possible.246 Full implementation 1033 
of such a decentralized approach requires considerable upgrading of the capacity of peripheral facilities 1034 
to manage complex patients. Such facilities should be supported by easy, routine communication with 1035 
treatment initiation centers and expert providers.  While a country or region may often have many DR -1036 
TB cases in the aggregate, peripheral facilities may have very few if any MDR -TB patients at any given 1037 
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time. Thus, experience is lacking, and decentralized needs to occur in tandem with close support from 1038 
experts, even those experts are accessed remotely. 1039 
 1040 
1.5.3 Preventing resistance acquisition 1041 
While diagnosis and prompt treatment are central to tackling the TB epidemic, minimizing the risk of 1042 
further resistance acquisition, both to existing first- and second-line drugs and new drugs, is also 1043 
paramount. This includes addressing the drivers of TB drug resistance listed above through 1044 
programmatic quality improvement (Section 1.1), but also avoiding the use of standardized regimens in 1045 
the absence of DST wherever possible. Finally, antibiotic stewardship entails ensuring that new drugs 1046 
are used in tailored, effective multidrug regimens for all patients with DR- TB, not just those with limited 1047 
therapeutic options. Such use also needs to be supported by expanded TB drug-resistance surveillance 1048 
(to replace intermittent, expensive DR -TB surveys). 1049 
 1050 
As with drug-susceptible TB, treatment of latent DR- TB may significantly impact the epidemic in the 1051 
long term. Currently at least two trials are evaluating different prevention regimens for individuals in 1052 
close contact with MDR/RR TB patients.232 In addition, WHO released a conditional recommendation in 1053 
2018 supporting the use of individualized preventive treatment for contacts of MDR/RR TB patients who 1054 
are at high risk of progressing to disease.247 Given the high morbidity and mortality associated with DR- 1055 
TB, preventive treatment of these high-risk contacts, including children and people living with HIV, is a 1056 
priority. 1057 
 1058 
1.5.4 Increasing DR- TB as global health security threat – implications for donor financing 1059 
The cost of treatment for MDR/RR TB, ranges from estimates of US$1,218 in low-income countries to 1060 
US$83,365 in high-income countries248. The high cost has been a significant barrier to scaling up 1061 
treatment to date. The Stop TB Partnership estimated that in 2017, US$2 billion was required to fund 1062 
DR- TB care; it is expected to increase to US$3.6 billion by 2020.55 Funding at this level is unlikely to be 1063 
sustainable for many high MDR/RR TB burden countries; the BRICS countries (Brazil, the Russian 1064 
Federation, India, China, and South Africa) are notable exceptions. As a result, funding to support DR- TB 1065 
programme implementation will likely be required from international sources, even in countries with 1066 
the capacity to fund their own DR- TB programmes. The current and future projected economic costs 1067 
associated with DR-TB, provides a compelling rationale to justify increased donor financing, even in 1068 
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middle-income countries transitioning out of donor eligibility249,250.   We discuss the implications of this 1069 
further in Section 3.  1070 
  1071 
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Section 2: Investing in TB Research and development 1072 
Despite causing more than one billion deaths during the last two centuries,251 TB remains poorly 1073 
understood. Although we can and must do more to broadly implement currently available TB control 1074 
tools and strategies,  achieving an end to the epidemic will require answering fundamental questions 1075 
about TB and developing new biomedical tools to accelerate our progress toward that goal.252 The 1076 
urgency of boosting our investment in TB R&D to enable these transformative advances  demands that  1077 
governments and their partners in high- and middle-income countries  commit now to sustained, 1078 
increased funding of these efforts.  The UNHLM underscored the crucial role accelerating TB R&D plays 1079 
and will continue to play in achieving an end to  the TB epidemic. Building on that call to action, here we 1080 
highlight R&D priorities and provide an economic rationale for why investment in these R&D priorities is 1081 
critical to success.  1082 
 1083 
1084 
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2.1 Biomedical research priorities  1085 
Future successes in developing new diagnostics, therapeutics, and vaccines for TB fundamentally will 1086 
require a better understanding of the pathogenesis of TB disease. In this regard, a key basic science 1087 
priority is identifying the correlates of risk for progression to disease.  An intensified search for 1088 
biomarkers associated with protection from disease,253 as well as the development of better animal 1089 
models, are among other priorities.  Large gaps also exist in understanding TB pathogenesis and the host 1090 
immune response, especially in children254 [Panel 4] and in individuals co-infected with HIV.255  1091 
Nonetheless, promising preclinical efforts exist that must be significantly expanded. These include using 1092 
computational modelling to better understand complex biological interactions between pathogen and 1093 
host,256 high-throughput host genomic screening to identify RNA signatures257 associated with the risk 1094 
for disease, and improved animal models of TB latency258.   1095 
 1096 
To accelerate the development pipelines for diagnostics, therapeutics and chemopreventive strategies 1097 
and vaccines, it is imperative to develop an integrated research strategy and agenda to close cross-1098 
cutting gaps in TB R&D (Figure 6, Appendix Figure xx).  Outlined below are key research priorities, 1099 
including those outlined recently in the US  National Institute of Allergy and Infectious Diseases (NIAID), 1100 
Strategic Plan for TB.  This Plan and similar multi-pronged, multi-disciplinary efforts are essential to 1101 
significantly advance TB R&D and end TB.259,260  1102 
 1103 
2.1.1 Diagnostics 1104 
With nearly four million people estimated to have undiagnosed or unreported TB, including an 1105 
estimated 558,000 people with undiagnosed, drug-resistant TB,5 the importance of having rapid and 1106 
accurate diagnostics at entry into TB care cannot be overstated. Early, accurate diagnosis together with 1107 
drug susceptibility testing at the time of diagnosis is key to breaking the cycle of transmission, enabling 1108 
patients to be quickly started on an effective TB regimen. Investments in R&D for TB diagnostics have 1109 
led to the progressive introduction of six new diagnostic tools since 2005. These have helped overcome 1110 
major barriers in identifying drug-sensitive and drug-resistant forms of M. tuberculosis, including cost, 1111 
complexity, slow time-to-result, and low accuracy.261 An additional 45 candidates are in the TB 1112 
diagnostic pipeline.262  Unfortunately, many of these are molecular technologies that are unlikely to 1113 
meet the three most important needs of high-burden low- and middle-income countries (LMICs) as 1114 
described below.  1115 
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For high-burden, low-resource settings, the first priority is an easy-to-use, low-cost, non-sputum-1116 
based263 rapid diagnostic test that can identify individuals with active TB and can be incorporated into 1117 
active case-finding strategies or used in primary care facilities (Appendix Panel xx). Modelling has shown 1118 
that a triage test,  implemented at the community level and used in combination with a confirmatory 1119 
test (e.g., GeneXpert), could close case detection gaps and reduce incidence by 19% and mortality by 1120 
37% over ten years.264  The second priority, highlighted in Section 1.5, is rapid tests for drug-resistance 1121 
that would help direct patients to appropriate treatments and safeguard medicines against antimicrobial 1122 
resistance.265,266 Priority three is an incipient TB in vitro diagnostic to identify individuals at high risk of 1123 
progression from latent TB infection to active disease. This in vitro diagnostic  would enable targeted 1124 
preventative treatment in communities as a prerequisite to TB elimination in the absence of an effective 1125 
vaccine. 1126 
 1127 
Achieving priority one requires identifying a suitable host and microbial biomarkers and biosignatures 1128 
(primarily antigen, antibody, or a volatile organic compound). Several promising diagnostic biomarker 1129 
combinations have been identified that are undergoing validation or being transferred to point-of-care 1130 
platforms.267,268 If successful, a triage test could be introduced by 2020; however, given high candidate 1131 
failure rates and few priority one candidates in the biomarker pipeline, additional funding is needed to 1132 
enrich the pipeline. Expansion of the drug susceptibility testing menu is underway for existing molecular 1133 
platforms, and next-generation sequencing tools show promise; however, further translational work is 1134 
required to make them affordable and deployable in high TB burden countries.269,270 Similar to the triage 1135 
test, a breakthrough in biomarker discovery is necessary to diversify the incipient test pipeline, which is 1136 
currently is sparsely populated.271 1137 
 1138 
2.1.2 Therapeutics  1139 
Development of markedly improved therapeutics could rapidly accelerate efforts towards ending TB.  1140 
The principal desired characteristics are shorter, non-toxic, patient-friendly treatment regimens that can 1141 
be implemented widely.272 Preferably, the individual components of improved therapies should focus on 1142 
either novel targets or targets that do not have cross resistance with available drugs.  Since 1143 
approximately one million new TB cases occur in the pediatric population each year, it is also critical that 1144 
new TB therapeutics be formulated to be appropriate for and effective in children as well as in adults.273 1145 
 1146 
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Developing novel, safer, shorter, and simpler regimens will have to overcome many challenges.  The 1147 
existing drug regimens to treat drug susceptible TB are remarkably effective, largely non-toxic and 1148 
extraordinarily inexpensive.  New drugs are unlikely to be tested individually but added to existing 1149 
regimens and tested for non-inferiority and safety rather than superiority.  As a consequence many of 1150 
the newer drugs are being tested on drug-resistant TB, where the effectiveness of current regiments are 1151 
limited and smaller trials in a defined targed population are feasible.  In addition to the research costs of 1152 
preclinical development and Phase I and II clinical trials, the lack of reliable, validated biomarkers that 1153 
can be used to predict the duration of therapy necessary to cure virtually all patients treated with a 1154 
given therapy.274 The findings of three recent Phase III trials275-277 , which failed to shorten TB therapy for 1155 
drug-sensitive TB despite promising Phase II data, clearly demonstrate how the lack of predictive 1156 
biomarkers constrains clinical research.  The lack of predictive biomarkers is particularly problematic 1157 
because, due to their complexity and long duration, the cost of late-stage clinical trials of novel TB 1158 
regimens is so high.   1159 
 1160 
During the past decade, remarkable progress has been made in the search for new TB drugs and 1161 
therapeutic regimens. In the early 2000’s, there were no new drug candidates to treat latent TB; the 1162 
pipeline has more than 30 compounds (although few are new chemical entities), including several drugs 1163 
in late-stage product development (Appendix Table xx).  Two novel drugs have received conditional 1164 
regulatory approval.5  Because of the pipeline growth, it is now feasible to investigate novel 1165 
combinations of drugs and new therapeutic regimens.  New regimens currently in Phase 2 and 3 clinical 1166 
trials show considerable promise and may enable much shorter durations of treatment —even for the 1167 
most resistant forms of extensively drug-resistant TB—than what is currently recommended.278  1168 
Furthermore, a two-month universal regimen, active against all forms of TB, may be  possible within the 1169 
next decade.  This would offer the potential to shorten and simplify treatment strategies and drug-1170 
susceptibility testing needs,279  and  should be a high funding priority in the next decade  The potential 1171 
utility of a pan-TB regimen must be considered together with person-centered approaches to treatment, 1172 
tailored to pharmacogenetics, co-morbidities, and drug co-administration, as well as the risk of new 1173 
forms of resistance.280   A diversified portfolio of therapeutic products offers the best  hope for long-1174 
term success; however, substantial investment in the short-to-medium term is needed to guarantee 1175 
those products make it to market.  1176 
  1177 
 1178 
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2.1.3 Vaccines and Chemopreventive Strategies 1179 
Prior to the antibiotic era, evidence existed to indicate that remarkable protection against TB could be 1180 
produced by latent TB infection, and that BCG was protective in some populations but not others.281  Yet 1181 
today, as highlighted in section 0, BCG remains the only available vaccine—one that is more than 100 1182 
years old, has variable effectiveness in preventing adult pulmonary TB, and is not recommended for 1183 
children who are infected with HIV. Despite compelling evidence from models demonstrating that a 1184 
vaccine with 60% efficacy could avert 70 million TB cases within 25 years if given to only 20% of at-risk 1185 
adults, 282 progress towards developing viable vaccines has been hindered by numerous scientific and 1186 
funding challenges.   In constrast to drugs, vaccines are given to healthy people to prevent illness. Thus, 1187 
the stringency in being certain that candidate TB vaccines are as safe as possible represents a high bar. 1188 
Also, because many individuals who will never be infected have to be vaccinated to demonstrate 1189 
protection in a smaller group infected with Mtb, trials require large populations and access to 1190 
sophisticated laboratories. 1191 
 1192 
Currently, 14 candidate vaccines in the pipeline that have shown some degree of protection against TB 1193 
in animal models are now in human clinical trials.274 Some are live recombinant vaccines (for example, 1194 
BCG with added antigens and genes to elicit strong immune responses, or genetically attenuated M. 1195 
tuberculosis); others are live virus vectors expressing multiple antigens of TB to provide long-lasting 1196 
immunity (e.g., recombinant  cytomegalovirus [CMV] vectors expressing TB antigens). 282   To date, only 1197 
two Phase III preventive TB vaccine studies have been published, one using an inactivated whole-cell 1198 
mycobacterial vaccine (M. obteneuse)  reporting <40% protection in adults with 283 and the other 1199 
evaluating the modified vaccinia Ankara virus expressing antigen 85A (MVA85A) to boost the 1200 
effectiveness of the BCG vaccine in infants, which failed to show protection.284,285 1201 
 1202 
However, two new Phase IIb trials offer new promise for vaccines against TB.286  Revaccination with BCG 1203 
of South African adolescents, who received BCG as infants but were not exposed to Mtb (Quantiferon-1204 
negative),  provided 45% protection against TB.287  In high burden countries, a high percentage of 1205 
individuals have been previously exposed to or latently infected with M. tuberculosis, and no vaccine has 1206 
previously been reported to provide protection to tuberculin-positive individuals.  A new subunit TB 1207 
vaccine,  with two Mtb antigens in an adjuvant that has been effective in vaccines against zoster and 1208 
malaria, M72AS01E, tested in several thousand adolescents in 3 sub-Saharan countries, showed 54% 1209 
protection overall, and notably 87% protection in those under 25 years.288  These results emphasize the 1210 
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importance of clinical trials and suggest that targeting vaccines to adolescents may provide optimal 1211 
protection.  It is only from searching for correlates of protection in human trials that necessary and 1212 
sufficient mechanisms of protection can be discerned, which could  shorten the time and expense of 1213 
future trials. 1214 
 1215 
Clearly these encouraging results need to be validated and extended, particularly in different 1216 
geographical situations.  But they make clear that, despite challenges, the scientific prospects for 1217 
developing a safe and effective vaccine to prevent TB are more promising than ever before; an increased 1218 
focus on early-stage research has led to a robust pipeline, and new technologies, which are providing 1219 
unprecedented scientific opportunities.289  Vaccines represent the most cost-effective intervention to 1220 
prevent disease and death.  In the case of TB, long-term and sustained investments will be necessary to 1221 
build on these promising results, but the returns even from a partially effective vaccine would be vey 1222 
great318.  1223 
 1224 
 1225 
2.1.4 Population, policy, and implementation research priorities  1226 
Progress towards ending TB has been limited because existing tools have been ineffectively 1227 
implemented and the currently used control strategies used are outdated. Greater national and global 1228 
investments in population, policy, and implementation research capacity will be required to enable the 1229 
scaling of effective approaches.97 In particular, implementation research is needed to understand how to 1230 
improve care cascades, i.e., find patients earlier, evaluate them quickly, and provide effective treatment 1231 
resulting in a  cure.   Population research to characterize the factors that drive TB transmission within 1232 
families and communities , particularly in high TB burden settings, is also critical for developing 1233 
strategies to interrupt Mtb transmission26  While research on sensitive, inexpensive point-of-care 1234 
diagnostic tests continue, active screening strategies could be implemented with existing technologies, 1235 
including automated X-radiography in contacts and high risk groups in high burden countries, followed 1236 
by culture or Xpert testing diagnosis,  in view of the strong evidence from surveys showing that 20-30% 1237 
of TB cases globally are asymptomatic.5,148, 174.   1238 
To optimize treatment outcomes, differentiated strategies for providing patient-centred care and 1239 
supporting treatment adherence must be developed in concert with the creation of new therapeutic 1240 
regimens.290-292 Likewise, research is necessary to determine the most efficient and cost-effective TB 1241 
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prevention therapies.  The potential of digital technology to overcome weak health system 1242 
infrastructures, enhance TB program quality, and improve disease surveillance, remains largely 1243 
untapped. While numerous disparate pilot studies have been conducted evaluating IT, e-Health, and 1244 
connectivity solutions, 290,293-296 future studies should be guided by a comprehensive research agenda 1245 
underpinned by a commitment from countries and funders to translate evidence to action at scale.  1246 
 Cross-cutting all of this, mechanisms must be identified and implemented to strengthen the 1247 
infrastructure and capacity of countries to absorb--in terms of both speed and scale-- innovations, as 1248 
well as to rapidly translate research findings into policy.297 For instance, the Initiative for Providing 1249 
Affordable & Quality TB Tests (IPAQT)298 provides a proven model for incentivizing the uptake of new 1250 
diagnostics among private sector providers in India; however, it has yet to be translated into a replicable 1251 
model and implemented in other countries. In part, this reflects the need for improved implementation 1252 
research capacity in LMICs to realize the benefits of investment in TB R&D.4 The role of trans-national 1253 
research networks to build such infrastructure and capacity is essential. 1254 
 1255 
2.2 The cost of inaction in R&D 1256 
The human costs of failure to develop and implement new and improved interventions is unacceptably 1257 
high.  Even in the WHO  best case scenario where treatment coverage was extended to 90% of persons 1258 
with TB and 90% were successfully cured  (substantially higher than what global estimates indicate, e.g. 1259 
notification is 65% for Ethiopia, 72% for india; few high burden countries have data on cure rates),5 we 1260 
estimate that there would be nearly one million unaverted deaths with current technologies (Figure 8).  1261 
To achieve these goals would require unprecedented case finding, treatment completion and 1262 
prevention, underscoring the important need to close gaps with scientific discovery and programmatic 1263 
innovation.    1264 
 1265 
The potential economic value of new tools is illustrated by modeling analysis in three different country-1266 
settings –India, Kenya and Moldova, illustrated in Figure 9, leveraging an approach where the value of 1267 
lives lost prematurely was derived using value of statistical life estimates (See Appendix for 1268 
methodology).94,299,300  Optimal implementation of existing evidence-based strategies to improve the 1269 
care continuum for active TB in each of those countries will still leave millions of deaths unaverted over 1270 
the next 30 years.  The value of the loss associated with TB mortality is, on average, $32bn per year in 1271 
India; $2.7bn in Kenya; and $35mn in Moldova.  However, these estimates are likely to be 1272 
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underestimates since: (i) they arise from an arguably ambitious scenario, of reducing losses in the care 1273 
cascade to 10% and delays by 25%, and (ii) they do not account for opportunity costs associated with 1274 
underaverted disease that does not lead to deaths, nor the financial burden placed on the health system 1275 
associated with this underaverted disease burden. 1276 
 1277 
It is fair to ask why there is such a gap in  investments in TB R&D.  There are many reasons:  The most 1278 
obvious is that the burden of disease falls on low and middle income countries which are least able to 1279 
afford new expensive tests and drugs.  As a relatively low prevalence disease and a high latently infected 1280 
population, efficacy testing of new tools will require large and lengthy trials. Finally, new tools are only 1281 
as effective in controlling the disease as are health systems able to implement them, and hence 1282 
improvements in health systems are critical. Nonetheless our analysis clearly demonstrates that further 1283 
tools, particularly tools for primary prevention will have a profound return on investment, insofar as 1284 
they prevent these needless TB deaths. Furthermore, it validates the argument that greater spending in 1285 
TB research is likely to bring important economic benefits and have a disproportionately beneficial 1286 
impact on health outcomes in LMICs.93.  It also underscores how proposed investments in R&D- 1287 
estimated to be US$8.7 billion over the next 4 years134  represents an excellent ROI.  If new tools were 1288 
developed that would enable reaching WHO’s targets, it is estimated that the ROI of each dollar, 1289 
depending on the value per DALY and the assumed discount rate, would be $16-82318.  1290 
 1291 
2.3 Reaching global TB R&D goals 1292 
Despite powerful public health and economic rationales for investing in TB R&D—essential for producing 1293 
breakthrough technologies and strategies to end TB, as outlined above—a significant gap in financing 1294 
remains. There are many reasons for this, including the lack of financial incentives to produce new tools, 1295 
the cost and duration of clinical trials, and the lack of compelling demand by affected countries.  It is a 1296 
slow and quiet killer compared to malaria and HIV, and few new interventions have been demonstrated 1297 
to be successful.   Global funding for TB product development was US$726 million in 2016,262 a mere 1298 
one-third of the annual funding called for by the Stop TB partnership, and  far less than is desireable to 1299 
achieve the kinds of R&D breakthroughs that have characterized HIV research over the last two 1300 
decades.134 Modelling analyses have suggested that current funding levels may be sufficient to realize 1301 
some key, near-term successes, e.g., a triage test and regimens for DR- TB based on repurposed drugs, 1302 
but that a multiple of current levels funding – but perhaps a substantial multiple -  is needed to enable 1303 
the development of truly transformative treatments and prevention tools (e.g., an incipient TB test, new 1304 
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vaccines).301,302  Closing the funding gap of at least US$1.3 billion per year will require high-income 1305 
countries to sharply increase their investments in TB R&D, in tandem with increased efforts from LMICs, 1306 
particularly BRICS, as well as the development of creative funding models that enhance industry 1307 
commitments.   1308 
 1309 
 Currently, 89% of investment in TB R&D comes from non-commercial sources — that is, governments 1310 
and philanthropies. US public agencies alone support 44% of all TB-related research globally.262 Only a 1311 
small fraction of the public funding for TB R&D comes from LMICs.303 Increasing contributions from LMIC 1312 
governments so that their total share of TB R&D matches their share of the global economy (i.e., 36.5%), 1313 
as has been proposed by a WHO expert group, would generate an additional US$146 million per year, a 1314 
26% increase in total global R&D financing. Given that late-stage clinical trials represent a critical funding 1315 
bottleneck, a self-funded BRICS/LMIC clinical trials network, which is focused on bringing innovative 1316 
tools through the regulatory pipelines, would be another way for high-burden countries to carry a 1317 
greater share of the TB R&D costs. It would be possible to increase public contributions further if some 1318 
HICs (or philanthropies) were willing to match increased contributions from LMICs, as Switzerland 1319 
offered to do in order to stimulate LMICs to contribute financing for several WHO-selected R&D projects 1320 
in 2014.304 This type of “matching grant” could increase total R&D to US$861 million per year, a 52% 1321 
increase over the status quo (Appendix Table xx). Matching funding from international donors and high-1322 
burden countries  could also ensure TB  R&D is more ‘needs driven’ and address the problem of ‘free-1323 
riding’, whereby countries withhold resources as long as others cover the costs.305      1324 
 1325 
Meanwhile, industry investment in TB R&D has stagnated, while R&D for other infectious diseases have 1326 
seen meaningful funding increases.262  UNITAID, through  small taxes on international air travel is is an 1327 
increasingly important source of funding for  TB R&D, providing US$215 million in 2018 for a variety of 1328 
innovative research  projects.  However, more creative models to secure private investment, 1329 
collaboration and partnership are needed to close the funding gap. Examples include the TB Drug 1330 
Accelerator, a collaboration between pharmaceutical companies and research institutions, which has 1331 
had several early successes in addressing the shortage of new TB drugs by funding early-stage TB drug 1332 
discovery,306and the Global Health Innovative Technology Fund (GHIT) model, a Japanese government 1333 
funding mechanism that leverages matched funding from industry.307 308  Other  funding mechanisms 1334 
including ‘downstream investments or ‘pull’  strategies (that promise reward for successful product 1335 
development) have been successful in the pneumococcal vaccine development,  and have    potential 1336 
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role in funding TB  R&D.309  The Life Prize (Appendix Panel xx) offers a novel model to stimulate drug 1337 
development, rewarding researchers and developers fully and upfront for their investments, thereby de-1338 
linking the financing of R&D from product prices and sales and promoting access and affordability as 1339 
well as appropriate use of resulting products.   1340 
 1341 
While these various options could represent an important increase, funding will still be far short of the 1342 
US$2 billion annual target. This shortage highlights the inescapable conclusion that HICs must contribute 1343 
more. To ensure the necessary increased investment from HICs, TB R&D must be understood as an 1344 
important global public good that will yield substantial economic dividends, as we highlight in Section 3.  1345 
Greater investment is also essential to address negative cross-border externalities that TB, particularly 1346 
DR -TB, poses and as central focus of the broader antimicrobial resistance research agenda. Hence, 1347 
strong advocacy for increased R&D funding to science ministries and research-oriented pharmaceutical 1348 
companies must occur in tandem with advocacy to international donor agencies.  1349 
  1350 
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Section 3:  Sustainable financing for TB 1351 
Everyone dedicated to achieving an end to TB – impacted countries, donor nations, the private sector, 1352 
foundations – must redouble their efforts to finance strategies that are working now and, more 1353 
importantly, strategies that have the real potential to make a significant impact in the coming years.   To 1354 
end TB, this Commission advocates for substantially more investment in all aspects of TB programming.  1355 
Increased domestic resource mobilization will be especially important, but new models of donor 1356 
financing that can catalyze domestic investment must also be a priority.    Evidence on the cost-1357 
effectiveness and benefits of expanded financing for tuberculosis control suggests that such investments 1358 
will yield a high return.310 1359 
 1360 
3.1 Economic evaluation of TB control interventions 1361 
3.1.1 The basics of TB economics 1362 
In this section we will distill a highly heterogeneous literature311 into indicative values of key economic 1363 
parameters. The section will focus on two such parameters: the cost required to avert a TB death and 1364 
estimates of benefit to cost ratios for TB control efforts. An additional important question is that of the 1365 
cost required to meet goals and we provide an approximation that is broadly consistent with this 1366 
Report’s goal of reducing the global TB death rate by 90% compared to 2015 levels, estimated to be 2 1367 
per 100,000.  Such estimates of cost are intimately bound with questions of revenue generation or 1368 
finance and are dealt with in the finance section of this report. Benefit to cost and cost effectiveness 1369 
ratios in this section will be generated under the same sets of assumptions as are the total cost 1370 
estimates of the domestic finance section (section 3.2). 1371 
 1372 
3.1.2 Costs per death averted 1373 
The literature312 contains multiple estimates of different indicators of program effectiveness for 1374 
different interventions in different environments and with different assumptions about how much in the 1375 
way of health system strengthening costs should be included in the cost estimates. The literature is far 1376 
less well developed in assessing to whom costs and benefits accrue, distributional questions. The 1377 
diversity of the literature poses problems for the high-level message objective of a report like this, but at 1378 
the same time it provides multiple valuable starting points for analysts with different objectives and 1379 
interests. Such estimates meet the objective of positioning our thinking even though the numbers 1380 
themselves make no claim to portray any particular set of conditions.  1381 
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 1382 
3.1.3  The ratio of benefits to costs for TB control  1383 
Benefits are estimated using methods that are standard in many governments’ (and the OECD’s) 1384 
guidelines for economic evaluation of projects.311 Within the OECD structure, this Report uses the 1385 
conservative (low) value of 0.7% of per capita income as the value of reducing mortality risk for an 1386 
individual by 1/10,000 for one year.  Although these results have been generated for this report using 1387 
conservative assumptions, the estimates here suggest that recent economic analyses undertaken by the 1388 
consulting firm KPMG,313 estimating cost of failing to respond to the TB epidemic, did not fully capture 1389 
the value gained from successful TB interventions. Rather than convey a highly heterogenous range of 1390 
estimates, we chose instead to rely on recent efforts to aggregate the literature.5,94,252  These efforts 1391 
provide estimates of cost per death averted that are typically stated implicitly rather than  explicitly 1392 
(Table 6).  Acknowledging major heterogeneity and uncertainty, it is reasonable to think that the cost 1393 
per death averted from drug sensitive TB would be in the range of US$5,000-10,000 and for DR-TB, 1394 
US$15000-20,000. 1395 
 1396 
Using US$7000 as an approximation of the cost per TB death averted and the 0.7% of GDP approach to 1397 
valuation, we arrive at a benefit-to-cost ratio for TB interventions of 7:1. This figure reflects the Stop TB 1398 
estimate314 in Table 6 for multi-intervention programs required to sharply reduce TB mortality and 1399 
hence can be viewed as an average across the range of required interventions.  Other estimates have 1400 
been higher.312,315 And as noted, KPMG found much lower (although still attractive) values using a very 1401 
different methodology.  Uncertainty concerning a specific value abounds.  But no serious uncertainty 1402 
attaches to the conclusion that the value of benefits exceeds the value of costs by more than a factor of 1403 
2 or 3. 1404 
 1405 
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3.1.4  Costs of ending TB in a generation 1406 
As TB incidence declines over time, both because of expanded control efforts and (probably) favourable 1407 
trends in poverty and other risk factor reduction, it is reasonable to project declines in needed 1408 
expenditure to keep TB deaths at very low levels.  Initially, if TB deaths were to be reduced by 90% from 1409 
the current level of 1.7 million per year to under 200,000  per year the additional expenditure required 1410 
would be on the order of: 1411 
 1412 
1.5 million deaths per year averted x US$7,000 per death averted  US$ 10 billion per year 1413 
Obviously, it would be impossible to scale up within a few years and early investments will yield 1414 
reduction in cases and costs.  However, a plausible cost trajectory for ending TB in our generation would 1415 
be a rise from current expenditure by, perhaps US$5 billion per year, followed by a reduction to a long-1416 
term level of US$1 to 2 billion per year by the early 2040s.  This number reflects a reduction in incidence 1417 
and hence treatment costs that ending TB mortality will require.  This Commission makes no attempt at 1418 
precision concerning this number in the belief that our basic understanding of the relevant determinants 1419 
of cost remain highly imperfect: expressing precise numbers is more likely to mislead than inform.  That 1420 
said, these numbers provide a reasonable approximation of the magnitude involved. 1421 
 1422 
3.2 Domestic Financing for TB 1423 
Section 3.0 makes the case for the economic benefits of investing in TB. In this section,  we examine the 1424 
extent to which TB programmes currently rely on domestic sources of finance in high- burden countries; 1425 
and the influence of domestic financing on the sustainability, efficiency, and equity of TB funding. In 1426 
addition, we explore the potential for rapidly increasing domestic financing for TB in the coming five 1427 
years. Finally, we highlight the importance of investing in NTPs, and other domestic funding agencies of 1428 
TB services, to allocate, distribute, and manage domestic TB resources; recognizing that it is essential to 1429 
develop the capacity to ensure increased financing is spent effectively to end the epidemic. 1430 
 1431 
3.2.1 The pivotal role of sustained domestic financing for TB 1432 
Improved domestic financing for TB is one of the success stories in global health over the past two 1433 
decades. By 2017, 84% of funding for TB came from domestic sources. This high proportion reflects a 1434 
consistent pattern of increased commitment to TB from high-burden countries. From 2007 to 2017, 1435 
global funding for TB doubled, with much of the increase coming from Brazil, Russia, India, China, and 1436 
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South Africa (BRICS). On average, the BRICS have domestically financed 95% of their public TB 1437 
expenditures over the past decade 316.   1438 
 1439 
Outside of the BRICS, the picture of domestic funding for TB is complex, reflecting a general scarcity in 1440 
health sector resourcing and capacity.  In 2017, less than half of public funding for TB in low-income 1441 
countries came from domestic sources. Nonetheless, the trend over time is promising; on average, low-1442 
income countries doubled their domestic financing of TB between 2007 and 2017, with a rate of 1443 
increase similar to that of international TB funding to their countries317. Not all low-income countries are 1444 
following this trend, and there is room for improvement: the current proportion of the domestic 1445 
contribution to public TB expenditure ranges from under 1% to 24%317. Likewise, in lower-middle income 1446 
countries, the proportion of domestic public funding ranges from 7% to 88%317, with the average  1447 
growth in domestic TB financing stable until 2013, but doubling since then.   1448 
 1449 
3.2.2 Who provides domestic finance, and how does it flow to TB?  1450 
TB expenditures can be divided into those that flow through general health service provision and those 1451 
that flow through National Tuberculosis Programmes (NTPs). While  the proportional domestic 1452 
contribution to overall TB expenditure is generally are high, NTP specific expenditure and TB-specific 1453 
commodities are more reliant on international finance. In 23 of the 30 high-burden countries, NTPs 1454 
receive more than 80% of their funding externally317, with the Global Fund being a substantial payer for 1455 
TB commodities. This apparent dependency of NTPs on international finance has most likely arisen due 1456 
to disease specific allocation of international funds, rather than reflecting an overall lack of domestic 1457 
commitment. Ministries of Finance inevitably reduce domestic resource allocation to TB to the extent 1458 
that they perceive international finance to be available.   1459 
 1460 
Domestic financing for TB within countries can come from a range of sources. Ultimately it is 1461 
populations and corporate taxes who pay, but TB patients still face much of the burden in some 1462 
countries. Despite the policy of free or reimbursed TB care in most countries, patients with TB can still 1463 
incur substantial out-of-pocket payments for public TB services 248. Moreover, in several high-burden 1464 
countries, large proportions of patients seek and receive TB care in the private sector, paying for their 1465 
own care and treatment. Subsidizing and pooling these private domestic expenditures, an important 1466 
goal of broader UHC agenda, will have beneficial consequences in terms of financial risk protection318,319 1467 
and possibly health outcomes320 for those with TB.  1468 
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 1469 
3.2.3 Is the allocation of domestic finance to TB efficient?  1470 
Although many countries have increased their allocation of public monies to TB,  a mismatch remains 1471 
between funding levels and need, the latter defined in terms of the resources required to reach global 1472 
End TB targets 317. From a domestic public finance perspective however, need is not a sufficient criterion 1473 
to increase investment. Ministries of Finance will have requests to fund many other development and 1474 
health interventions that have potentially high returns. Hence, those advocating for increased 1475 
investment in TB, both within and external to governments, need to demonstrate that investment in TB 1476 
performs well, at the very least compared to other health sector investments.  Investments in TB hence 1477 
need to be efficient, defined as maximimising population health for any given level of funding. 1478 
 1479 
Increasingly countries are developing public finance processes that formally assess the return on 1480 
investment of different health sector interventions, rather than relying on global evidence. These 1481 
processes are being supported by improved data and understanding of the costs, effectiveness, and 1482 
long-term impacts of investment in TB on both health and economic outcomes.321  In the main, 1483 
supporting these efforts often work in favor of TB. In Malawi for example, a recent assessment to 1484 
determine the essential package of health care found that seven of the top 10 ‘best buys’ for health 1485 
sector budget prioritization were TB interventions.322 This mirrors systematic reviews of return to 1486 
investment of TB expenditures across several countries.146 supporting the assertion that increasing 1487 
domestic allocation to TB can improve the efficiency of the entire health sector. 1488 
 1489 
There is, however, room to improve the efficiency of TB expenditures, through improvements in the 1490 
delivery and implementation of TB services, as highlighted in Section 1. In some countries the split of TB 1491 
expenditures on TB commodities versus general service provision may not be optimal. Improvements in 1492 
health system strengthening are critical to ensuring that health staff at the front end of TB service 1493 
delivery receive the right mix of resources to provide high-quality patient-centered TB services 323.  Some 1494 
countries also have higher than average TB treatment costs, due to the over hospitalization of TB 1495 
patients, in particular those with DR-TB.  Nonetheless, the decentralization of DR -TB care in South Africa 1496 
illustrates the substantial additional funding that may be generated by reducing hospitalization for 1497 
patients, including those requiring intensive treatment for DR-TB 324 . Improved integration of TB 1498 
services may also support patient-centered care and reduce costs 325. Several new TB technologies, such 1499 
as shortened regimens, may reduce the costs substantially. More analyses on the efficiency of these 1500 
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different approaches to scaling up TB services  is necessary to help guide how countries can spend 1501 
funding effectively.326  1502 
 1503 
3.2.4 Can domestic funding for TB be substantially increased in the next five years? 1504 
Generating additional domestic financing for TB depends on: governments’ commitment to allocate 1505 
more funding to TB; the future potential for efficiency gains; and increases in the overall level of 1506 
available public finance. Increases in domestic financing for TB in the past two decades demonstrate 1507 
that countries experiencing GDP growth may be able to expand their funding of TB rapidly, and at the 1508 
same time reduce TB incidence327. In addition, the ability to raise domestic finance for TB from private 1509 
individuals and firms depends on the system of revenue generation and taxation structures. In recent 1510 
years, a range of innovative mechanisms, including earmarked taxation of alcohol and cigarettes, 1511 
government loan buy downs, in which a third party contributes to loan payment to open up social 1512 
spending and the expansion of health insurance coverage, have been explored to improve the financial 1513 
sustainability of the health sector, with positive consequences for population health 328. These 1514 
mechanisms have yet though to provide substantial funding for HIV,328 and there are considerable 1515 
questions as to their feasibility to raise high levels of funding for TB. 1516 
 1517 
Conducted in collaboration with the Lancet Commission, a team at the London School of Hygiene & 1518 
Tropical Medicine (LSHTM) and UCSF conducted an analysis examining the potential fiscal space for TB 1519 
for 28 of the 30 high-burden countries over the next five years (two countries excluded due to data 1520 
scarcity). Fiscal space analyses apply international public financing norms to current fiscal performance 1521 
to determine the extent to which funding can grow in a way that does not damage overall fiscal stability. 1522 
The financing sources examined included GDP growth, increasing public revenues, improving allocation 1523 
to the health sector, improving allocations to TB, and increasing the efficiency of public TB service 1524 
delivery. The researchers found that most high-burden TB countries can substantially increase public 1525 
domestic financing of TB. By 2023, countries such as Bangladesh, Zambia, China, and Indonesia can 1526 
potentially increase their annual TB expenditures more than five-fold, through a combination of 1527 
optimized resource allocation, revenue generation and improved resourcing of the health sector (Figure 1528 
10). In countries like Zambia, increased prioritization and efficiency of TB services would enable the 1529 
greatest resource mobilization for TB.  In countries like Bangladesh, China and Indonesia, governments 1530 
will need to commit to substantial policy action around revenue raising, such as increasing tobacco 1531 
taxation and the increased pooling of health sector funds.  Despite the potential impact of tobacco 1532 
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taxation highlighted in this analysis, we acknowledge the limitations of raising tax in the short term and 1533 
advocate for optimized resource allocation and improved resourcing of the health sector as the most 1534 
sustainable means of increasing financing for TB. 1535 
 1536 
3.2.5 Policy Implications 1537 
In summary, mobilizing domestic resources for TB will take policy action and commitment across 1538 
government, including Ministries of Finance and Ministries of Health.  Increasing tobacco taxation and 1539 
allocating those revenues to health is a clear policy action that can support financing TB elimination and 1540 
have positive benefits for persons with TB, but is a long term public health objective. Increasing 1541 
domestic public financing for TB in a manner that protects TB patients from catastrophic expenditures is 1542 
particularly important, and also serves a broader UHC agenda. 1543 
 1544 
However, it should not be assumed that high level commitment to this broad policy agenda is sufficient. 1545 
Rapid increases in domestic financing for TB will require enhanced capacity to allocate and spend 1546 
resources effectively and transparently to demonstrate results. A clearly defined accountability 1547 
framework to ensure commitments made at the high level meeting will be critical. In addition, NTPs 1548 
need to strengthen their ‘absorption’ capacity, otherwise the the rate at which additional financing is 1549 
disbursed in practice may be slow. The experience of HIV demonstrates it is possible to rapidly 1550 
strengthen progammes, but that strong systems are required to ensure efficiency and maximise health 1551 
outcomes. Effective, rapid disbursement will depend on the capacity of NTPS to mobilize expertise, 1552 
infrastructure, and sufficient human resources in a timely manner. Upfront support to NTPs to build the 1553 
mechanisms to absorb new funding, and fully participate in resource allocation and management 1554 
systems and processes within the health sector, will therefore be critical to ensure additional resources 1555 
are used.  The commitment of many HBCs over the past two decades is commendable, and many have 1556 
the space and willingness to do more, but achieving real increases in expenditures, beyond the current 1557 
rate will require concerted attention by all those working to end TB to absorb additional resources 1558 
effectively. 1559 
 1560 
  1561 
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3.3 Donor Financing for TB 1562 
3.3.1 Donor investments in TB 1563 
The potential for increased domestic health spending, economic growth, as mentioned in Section 3.1, 1564 
along with the recent rise of populism and protectionism,329 will inevitably shape external financing for 1565 
TB programs over the coming decade. Nearly all high-burden countries can substantially increase 1566 
domestic resources allocated to TB.  While many low-income countries still require donor financing for 1567 
TB, new opportunities exist to re-think how and where donor financing is allocated such that its impact 1568 
is maximal.   In this section of the report, we discuss the role of donor financing to catalyze domestic 1569 
efforts and invest in global public goods, especially in those countries transitioning out of donor finance 1570 
eligibility.  In addition, we highlight the potential benefits to donor partners of investing in TB, 1571 
economically and in terms of addressing the negative cross-border externalities that TB, especially DR- 1572 
TB poses.  Finally, we underscore the importance of sustained financing for the poorest countries and 1573 
advocate for continued investment to end the epidemic in those countries. 1574 
 1575 
3.3.1 Who is investing in TB programs? 1576 
According to the OECD’s Creditor Reporting System, international donors provided US$871 million for TB 1577 
prevention, diagnosis, and treatment in 2016 (the latest year for which   data are available),  69% of this 1578 
was expended by the Global Fund, of which the United States (US) was the major contributor.5  In 1579 
addition, the US disbursed US$179 million channeled via its own agencies and other institutions.  1580 
Between 2006 and  2016, approximately 46% of international donor expenditure for TB originated in the 1581 
US.5 The  next  largest  contributors were France (10%), the United Kingdom (9%) and Germany (6.2%).5 1582 
According to the Institute for Health Metrics and Evaluation (IHME), The Bill and Melinda Gates 1583 
Foundation was the largest non-state funder of TB activities, responsible for US$204 million of 1584 
disbursements in 2016, including $68 million allocated to the Global Fund, while other sources private 1585 
philanthropy spent $70 million, of which 14% was allocated to the Global Fund.330  1586 
 1587 
Development assistance for health (D.A.H) for TB has increased from US$30 million in 1990 to well over 1588 
US$1 billion in  2016, underscoring the substantial increases in international financing that have 1589 
occurred over that period, as well as the relative contribution of foundations, development banks, the 1590 
Global Fund and traditional bilateral funding. Nonetheless, current levels of funding for  TB still fall very 1591 
far short of the annual US$2.6 billion proposed in the Global Plan to End TB, outlined by the Stop TB 1592 
Partnership.134  1593 
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 1594 
3.3.2 How is donor finance being used? 1595 
Analyses of donor financing for health have traditionally tracked flows by funding source, channel, 1596 
recipient, and disease.  For this Commission, a team at UCSF and Duke University conducted an analysis 1597 
of development assistance for health (DAH) for TB broken- down into functions (Annex xx and yy).331 1598 
Global functions refers to transnational topics, including supporting global public goods such as R&D, 1599 
managing cross-border disease  spread and fostering leadership and stewardship.  The researchers 1600 
analyzed DAH for TB in the year 2015, using the OECD Creditor Reporting System, which provides 1601 
detailed information on aid expenditure.332 They found that in 2015, US$932 million in DAH was directed 1602 
towards TB-related activities.  Half of DAH for TB was disbursed to to lower MICs, 22% to LICs, 4% to 1603 
upper MICs, 23% to bilateral unspecified activities, and a small portion (0.4%) to regional efforts. Only 1604 
about one-quarter (24%) of DAH for TB was for global functions, supporting product development (17%), 1605 
population, policy and implementation research (PPIR) (3%), advocacy  and priority setting (2%), and 1606 
other global public goods (Figure 11).  Around three-quarters (76%) of DAH for TB supported country-1607 
specific functions, including  TB  programs for care delivery (52%)  and health system  strengthening 1608 
(24%).  Almost all (96%) of the health system strengthening support was TB specific, with  only 4% 1609 
directed at system-wide, cross-cutting health system strengthening.  These allocations highlight that 1610 
donor funds are being primarily targeted to support country-specific activities, especially those countries 1611 
with the highest burden, rather than  focused  on  global public goods.  The policy implications of these 1612 
findings are discussed below. 1613 
 1614 
3.3.3 Policy implications 1615 
To our knowledge the analysis outlined above is the first to determine how much TB-specific DAH is 1616 
devoted to supporting global functions versus country-specific functions.   Notably, this analysis does 1617 
not shed any light on trends in TB funding or how country-specific TB program funding is disaggregated 1618 
between DR-TB and DS-TB control efforts or provide granularity with DAH differs by disease burden or 1619 
country income group.  Nonetheless, the findings highlight the   need to increase  investment to support 1620 
Global TB functions, in addition to country-specific functions.  Although our baseline analysis cannot 1621 
prove that global functions are being neglected, prioritizing funds to these global functions should be 1622 
considered, especially as domestic resource allocation for TB increases.  In particular, this Commission 1623 
asserts that donor financing should increasingly be focused on the following functions (Appendix Table 1624 
xx):  1625 
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 1626 
Global  Functions 1627 
Supplying global public goods (GPG) - Greater investment in  global public goods, in particular TB R&D 1628 
for new drugs and technologies, are likely to bring important economic benefits and have a 1629 
disproportionately beneficial impact on health outcomes in low- and middle-income countries.93 New 1630 
tools deriving from TB R&D are also likely to provide financial protection and be most beneficial  to the 1631 
poorest-members of society, as shown by “extended” cost-effective analyses.319  The investment in HIV 1632 
R&D over the last two decades, leading to over thirty new drugs and numerous diagnostic and 1633 
preventive technologies, provides compelling evidence for greater investment in TB R&D.256  1634 
 1635 
Market-shaping  activities The Global Drug Facility (GDF), an arm of the Stop TB Partnership, serves an 1636 
important function  in this capacity, using donor financing to consolidate demand from different 1637 
countries to negotiate lower prices for TB drugs, attract additional suppliers, and incentivize innovation, 1638 
in particular for more expensive second-line agents and pediatric medicines.333-335  These kinds of 1639 
activities will remain important as countries increasingly assume co-financing and/or transition out of 1640 
donor eligibility, as they may have difficulty negotiating lowest possible prices or accessing concessional 1641 
prices for diagnostics.  As countries move away from donor funding, the global market for TB medicines 1642 
and diagnostics will surely become much more fragmented and the need for a global TB market 1643 
steward, such  as GDF, will become more important. In addition, the importance of GDF to facilitate  1644 
uptake of new diagnostic and therapeutic tools will also be essential as investment in R&D yield greater 1645 
successes in the coming years. 336 1646 
 1647 
Exercising leadership and advocacy -  An important, albeit often neglected global function of aid relates 1648 
to investment in health advocacy and priority setting.  This includes but is not limited to donor financing 1649 
to support civil society organizations (CSOs) as important catalysts for change.  While donor partners 1650 
have increasingly committed to supporting community engagement efforts over the last decade,337 CSOs 1651 
continue to lack recognition as legitimate partners at national levels, their impact undermined by lack of 1652 
resources for community initiatives.338 Recognizing that funding for HIV advocates and activists has been 1653 
crucial to global HIV efforts,339,340 this Commission affirms the importance of increased funding for TB 1654 
advocates as a global public good, deserving investment commensurate with the part they plays in 1655 
improving health outcomes.   1656 
 1657 
THE LANCET COMMISSION ON TUBERCULOSIS 
59 
 
Consideration should be given to increased investment in WHO’s Global TB Program, given its important 1658 
role in facilitating uptake of new policies, strengthening surveillance systems and providing technical 1659 
assistance.  A better-funded WHO would enable it to fulfill those functions more effectively.329  1660 
Independent regional initiatives such as those established to tackle malaria,341 that can provide locally-1661 
relevant, agile and responsive support to high burden countries may also be worthy of donor 1662 
investment. 1663 
 1664 
Country  specific functions 1665 
Targeted investment is needed for countries graduating from DAH.  Presently, 54% of country-specific 1666 
aid in our analysis is directed towards high burden, middle-income countries, many of which will soon be 1667 
ineligible for donor financing; based on their national GDP per capita, they are becoming ‘too rich’ to 1668 
qualify for DAH.  Unfortunately, many of these countries are likely to have large pockets of poverty and 1669 
avertable mortality from TB.  Here we propose targeted investments directed to social insurance 1670 
schemes that protect those at highest risk for TB.  Furthermore, we argue that sustained funding in 1671 
many of these countries, especially those with a significant DR- TB burden, is warranted given the global 1672 
security implications of failing to ensure TB control in these settings: 1673 
 1674 
DR-TB and management of cross-border externalities – As highlighted in Section 1, the high cost of 1675 
treatment for DR -TB, especially in middle-income countries248, has been a significant barrier to scaling 1676 
up treatment provision to date, and the cost will continue to rise over the coming years.55  Donor 1677 
partners, especially the Global Fund, are already investing disproportionately in DR- TB control activities.  1678 
Nonetheless, given the substantial weight of data demonstrating extensive cross-border spread of DR-1679 
TB, 342-352 DR- TB poses perplexing economic and health security issues for donor countries. It is 1680 
important that sustained funding for DR -TB control efforts, even in countries that will be soon 1681 
‘graduating’ out of ODA eligibility, be sustained to mitigate the cross-border threat that DR- TB poses.  1682 
Aligning DR- TB control efforts with the broader AMR agenda is also essential to maximize investment; 1683 
unchecked TB will be the single biggest cause of antimicrobial resistance related deaths by 2050.353   1684 
Funding for multisectoral, regional  1685 
 1686 
Protecting risk pools – Prisoners, people living with TB/HIV coinfection, migrants, refugees and 1687 
indigenous populations are all highly vulnerable to TB, and experience significant marginalization, 1688 
decreased access to quality services, and human rights violations.  These communities will continue to 1689 
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benefit from donor support, for example, through support for social health insurance schemes that 1690 
include TB services,319 even as domestic resources for health are increasing. 1691 
 1692 
Co-financing and catalytic funding - In addition to where DAH is spent, how it is spent is also crucial to 1693 
guaranteeing the impact of donor support.  Catalytic investments, such as those supported by the Global 1694 
Fund, offer examples of how new models of financing, through use of matching funds to incentivize 1695 
country allocation for priority areas, or multicounty funding mechanisms that address specific priority 1696 
areas such as developing innovative approaches to accelerate active case finding and scale up new tools 1697 
or facilitating re-tooling initiatives as new drugs and diagnostics because available.354    1698 
Notwithstanding the need for better data assessing the impact of these funding mechanisms, co-1699 
financing solutions provide an important pathway to ensure greater country ownership while also 1700 
ensuring sustained funding for TB activities even during the transition process. 1701 
 1702 
Ongoing support is needed to help the poorest countries.  By 2035, there are still likely to be around two 1703 
dozen low-income countries that will require direct country assistance for years to come.4 Donor 1704 
financing for these countries needs to increase substantially to make up for funding shortfalls over the 1705 
last few years.  Despite a small increase in funding between 2016 and 2017, it still fell very far short of 1706 
the annual $2.6B in DAH that is needed for TB according to the Global Plan.5  The moral imperative of 1707 
sustained donor investment in these countries should be highlighted – millions of individuals will 1708 
potentially die from TB in these countries without external assistance.  In addition, the scale of the 1709 
impact of those avoidable deaths on the global economy is substantial, as our analysis in section 3.0, 1710 
highlights.  Investing in TB control will reap economic dividends that will likely benefit both donor and 1711 
recipient nations.  Underscoring the importance of investing in TB as an important tracer for progress 1712 
towards UHC64 should also inform how and where donor funds are allocated.  As global momentum 1713 
builds towards achieving UHC, investment in TB as a disease of poverty is imperative to that progress.    1714 
 1715 
3.3.4 A new era of shared responsibility 1716 
The  UN HLM declaration, and the  stated commitment to shared responsibility highlighted how 1717 
priorities and approaches to TB  financing are evolving.  We are entering a new era of increased country 1718 
ownership and global cooperation.329,355  In addition, the architecture of donor financing for TB is 1719 
changing as high-burden countries mobilize additional resources for TB control.  Leveraging 1720 
concessionary loans from development banks356 and innovative financing mechanisms (e.g. social impact 1721 
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bonds, loan guarantees)134,329 should have  an increased role.   Such financing solutions  have great 1722 
potential, but they are no panacea.357  Strategies that can help increase domestic investment are crucial.  1723 
Even in low-income countries still reliant on donor support, the nature of donor-recipient financing must 1724 
evolve.  Partnership agreements between donors and recipients, as a tool to ensure ownership, 1725 
accountability, and transparency, should be encouraged.  By this mechanism, donors could also help 1726 
unlock domestic resources, by commiting  funds that pair global and national resources for shared 1727 
priorities.358 New models of donor financing that focus on results, encourage innovation and strengthen 1728 
government accountability to citizens rather than donors are also necessary.  One promising example of 1729 
a new financing strategy, is  the USAID’s Global  Accelerator to End TB which   was launched in Septemer 1730 
2018.  The Accelerator will seek to link financial support with performance-based  measurements  in 1731 
order to maximize resources,  while also leveraging additional resources from countries, private sector 1732 
partners and other local organizations.359  In addition to new funding mechanisms, new funding 1733 
partners, such as multinational business and corporate philanthropists, should be encouraged to close 1734 
TB funding gaps.  The opportunity for legacy impacts at national and global level, an oft-cited motivator 1735 
of such funders, will increase as TB elimination efforts become tangible. 1736 
1737 
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Section 4: Creating the enabling environment to end TB  1738 
In Section 4 we highlight the importance of an enabling environment to each country’s success in 1739 
responding to TB.  Figure 12 provides a framework for operationalizing country-owned responses to 1740 
drive progress towards ending TB and to leverage good practices in the TB response to advance other 1741 
Sustainable Development Goals.  This framework represents an idealized response and illustrates 1742 
mutually reinforcing functions performed by state and global actors.  These functions are person-1743 
centered, rights-based, and data-informed. The priority is ensuring high quality care for persons with TB 1744 
who present followed closely by a focus on active case-finding strategies and TB prevention 1745 
interventions targeted at high-risk groups.   A strong TB response needs to be guided by country-owned, 1746 
multisector and multi-stakeholder coordination, accountability and good governance at all levels to 1747 
achieve sustained long-term efforts. Civil society is a vital constituency to ensure that TB programs and 1748 
stakeholders are held accountable at global, national and subnational levels.   In addition, the 1749 
framework underscores the importance of addressing TB as a core component in achieving UHC.  While 1750 
countries are in varying stages of progress towards UHC, for high TB burden countries, prioritizing 1751 
investments in TB to realize UHC will be critical.  UHC, backed by donor assistance when needed, also 1752 
offers an opportunity to tackle TB with multisectoral initiatives that are consistent with the principles of 1753 
the Sustainable Development Goals. 1754 
 1755 
4.1 Ending TB is important on the pathway to achieving UHC 1756 
As this report highlights, progress towards ending TB ideally will occur together with achieving UHC. 1757 
UHC means all people have access to high-quality health services—at a minimum, health promotion and 1758 
primary care—at no or little cost at the point of service. This Commission asserts that ending the TB 1759 
epidemic must involve strong national TB programs that can prioritize specific TB care and prevention 1760 
functions within a progressive universalist pathway to UHC.  This pathway is a publicly financed 1761 
approach covering those core health-care services that directly benefit the poor, who are 1762 
disproportionally affected by TB.360  To this end, TB care and prevention functions should be addressed 1763 
specifically and included within essential service packages.361,362 Social insurance models that prioritize  1764 
diseases that disproportionately affect low-income and other vulnerable populations will automatically 1765 
incorporate TB. To realize the End TB targets, this Commission proposes to reach populations at highest 1766 
risk for TB early in the roll-out of such schemes. In countries with high TB burdens, maintaining a 1767 
separate TB budget and program within a broader UHC framework typically will prove efficient.  Even as 1768 
THE LANCET COMMISSION ON TUBERCULOSIS 
63 
 
the TB burden declines, ensuring that TB programs maintain a very visible position within primary care 1769 
budgets and Ministry of Health activities is advocated   1770 
 1771 
Several other system-wide frameworks are integral to a TB-inclusive UHC agenda.  These include 1772 
ensuring the uninterrupted availability of and access to appropriately regulated TB medications and 1773 
diagnostic tests, strong information and performance systems and new or merged risk financing 1774 
pools.363  Regulation should address how medical products are subsidized as well as the types of medical 1775 
professionals authorized to prescribe or dispense TB medicines.  High-burden countries will also need to 1776 
establish an optimal mix of skilled health workers to deliver services, and to design appropriate pay 1777 
incentives for health professionals to support scaling up the TB response as well as a broader UHC 1778 
agenda.364 Robust information systems that are sensitive to TB indicators365 and infection control 1779 
measures in health facilities are important.154 In addition, technical solutions applied to TB programs, 1780 
such as network optimization and quality management, as highlighted in Section 1, are necessary to that 1781 
UHC agenda, and underscore how success in ending TB is tied to each country’s success in ensuring high 1782 
quality health for all.366 1783 
 1784 
4.2 Social protection 1785 
The adverse financial consequences of TB on households resulting from lost income during long periods 1786 
of illness can be profound and long-lasting, as illustrated in Panel 3  To reduce the risk of 1787 
impoverishment from TB requires policies that protect patients and their households against ruinous 1788 
financial costs associated with TB.34 Especially in those settings where private sector care predominates, 1789 
strategies must be adopted that ensure financial protection and adequate quality of care, in both public 1790 
and private sectors.  This Commission argues that, as part of the UHC agenda, public finance should be 1791 
extended to private providers for TB care, and that private finance in public facilities (user fees) should 1792 
be minimized. Beyond public financing of treatment and case-finding, many TB patients also may need 1793 
economic and social support.  These measures, particularly, social support, can enhance treatment 1794 
adherence and positively affect clinical outcomes.142 1795 
 1796 
Social protection interventions—policies and programs designed to protect individuals from social and 1797 
economic risk367—are a promising approach to improving TB outcomes368,369 and achieving these larger 1798 
policy goals. Examples include cash transfers and nutrition programs offered as part of national policies. 1799 
Such interventions can contribute to successful TB outcomes indirectly by addressing social, biological, 1800 
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and structural determinants or directly by enabling access to care.66,370,371   Such interventions can 1801 
significantly affect tuberculosis trends by enhancing access to TB care and by mitigating the effect of TB-1802 
related catastrophic costs.372    1803 
 1804 
4.3 Sustaining top-level political support and leadership 1805 
Strong national and local political leadership creates an environment conducive to sustained attention 1806 
and funding.  To end TB, governments of high-burden countries will need to propose bold plans to end 1807 
TB rather than be content with modest incremental gains. Encouragingly, there is growing political 1808 
recognition that countries need to act now to address the TB epidemic. Since its establishment in 2014, 1809 
the Global TB Caucus,373 which supports 2,300 parliamentarians in 130 countries, has become a driving 1810 
force to mobilize political capital to address TB. TB legislation in the Philippines374 and Peru375 that 1811 
mobilized national finances to drive improvements in TB care and prevention, highlights successes that 1812 
can be achieved because political leaders in these countries championed the cause. In South Africa, key 1813 
political leaders from Ministries of Health and Finance have been instrumental in formulating a TB 1814 
investment case, to marshal additional resources to find new cases and treat more drug-resistant TB 1815 
(Figure 5).  Progress as dramatic as that envisioned in the End TB strategy can be achieved only when 1816 
each country’s leadership outlines a long-term strategy to combat TB within its borders, similar to 1817 
longstanding strategies established to fight HIV/AIDS.     1818 
  1819 
Effective leadership at the National Tuberculosis Programme (NTP) level is also a critical element of a 1820 
successful TB response and evidence of high-level commitment to addressing TB. The size and capacity 1821 
of the NTP’s central coordination team and the level of decentralization and integration of specific 1822 
services depend on many factors, including the country’s size, governance, administrative structure, and 1823 
TB epidemiology. However, chronic underinvestment in TB control efforts can undermine all aspects of 1824 
TB programming, including the caliber of NTP key personnel, human resource planning, capacity 1825 
strengthening, and supervision and monitoring of service quality. Empowering NTP managers to take the 1826 
necessary steps to institute effective strategies will require increased financing and recognition that NTP 1827 
leaders must play an inter-sectoral, convening role with stakeholders of other government ministries, 1828 
including finance, justice, labor, social welfare, housing, mining, and agriculture. Furthermore, a high 1829 
priority must be placed on ensuring that these leaders have access to senior government leadership 1830 
(Heads of Government and Ministers of Finance) who can authorize mobilization of funds to realize the 1831 
goals identified.   To ensure the high-caliber NTP leadership needed to fulfill these expanded roles 1832 
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demands that these managers receive adequate pay, reasonable autonomy, and opportunities to 1833 
maintain up-to-date technical knowledge.   1834 
 1835 
4.4 Maintaining multisectoral engagement 1836 
In the SDG era, addressing TB must occur as part of a broader multisectoral framework that addresses 1837 
key social determinants– especially poverty and overcrowding,376 malnutrition8, smoking,377 and air 1838 
pollution378 –clearly linked with TB and TB mortality.  Success will require collaboration among multiple 1839 
ministries, agencies, and civil society. The health sector, particularly the NTP, can play a key role in 1840 
identifying and communicating the potential health impact of policies on food security, improved 1841 
housing, poverty reduction, employment safeguards, and human rights protections for migrant, 1842 
prisoners, and other marginalized groups.364  Numerous policy tools, including taxes and subsidies, laws 1843 
and regulations, information and communication and improvements in urban planning, should be 1844 
employed to address these issues.  As highlighted below, accountability to address these determinants, 1845 
at both a national and subnational level may be valuable, especially in addressing issues such as tobacco 1846 
control and under-nutrition.   1847 
 1848 
While not disavowing the critical importance of a multisectoral agenda to address determinants of TB 1849 
disease, this Commission recommends that improving access to diagnostic, treatment, and preventive 1850 
services, especially for high-risk populations, should be the primary means of ending TB as a disease of 1851 
global public health significance, in most high burden countries.  Over the next generation, substantial 1852 
progress can be made by ensuring that individuals with TB can access curative treatment, and those at 1853 
highest risk for TB disease can access preventive therapy, especially since so many currently lack that 1854 
access.   Continued improvements in TB control tools and the systems for delivering TB programs 1855 
coupled with greater financial resource mobilization for health offer the most concrete likelihood of 1856 
ending the epidemic.94   1857 
 1858 
4.5 Strengthen civil society involvement in all aspects of the TB response 1859 
A critical lesson learned from HIV/AIDS response is that engaging stakeholders from the civil, public, and 1860 
private sectors requires national leadership to bring disparate actors together, overcome 1861 
communication barriers, enable policies, and scale up access to effective medical tools. Civil society 1862 
dramatically changed the global response to HIV/AIDS, making it a top priority at all levels and driving 1863 
unprecedented growth of donor support for lifesaving interventions.379 339  1864 
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 1865 
Until recently, few TB survivors or other people affected by the disease have served as public advocates, 1866 
in part because of TB’s curable nature, the  top-down orientation of TB control efforts, and the 1867 
persistent stigma of TB worldwide, the lack of funding to support community involvement in TB 1868 
programming.380,381 Fortunately, this is changing. A growing cadre of healthcare workers and students 1869 
who are TB survivors are using their dual perspectives and professional networks as platforms to call for 1870 
rights-based services and accelerated access to diagnostics, new treatment regimens, and vaccines.380 1871 
National and transnational TB activism is emerging as a vital force advocating for services in hard-to-1872 
reach populations, mobilizing communities and strengthening community systems. TB survivors can play 1873 
an essential role in creating incentives for political leaders to make difficult and risky decisions, by 1874 
generating public support for those decisions, and in holding leaders and service providers accountable 1875 
for how resources, commitments, and services are delivered.  1876 
 1877 
In the post UNHLM-era, the continued input of TB-affected civil actors is essential to ensure the 1878 
accountability of politicians and program planners. Recognizing their contribution as a global public 1879 
good, governments and international organizations must create conditions for civil society actors to play 1880 
an expanded role in the fight against TB, supporting their contribution through direct investments and 1881 
assembly to raise inconvenient truths. This should include involving such advocates in national TB 1882 
strategic planning processes, national TB research-agenda setting activities, and national and regional 1883 
accountability mechanisms. 1884 
 1885 
4.6 Strategies to reduce TB-stigma and ensure a human rights-based approach to TB   1886 
An important lesson from the HIV epidemic (and for global health generally) is that only by committing 1887 
to universal human rights for everyone can the highest available standard of physical and mental health 1888 
care be fulfilled.339  To uphold and defend the human rights of people with TB or those at most risk of TB 1889 
can bring down rates of infection and death.  Practical solutions are needed to expedite changes in the 1890 
laws, policies and public attitudes that violate human rights of vulnerable populations who might be at 1891 
particular risk of developing TB disease, including people living with HIV, prisoners, refugees and 1892 
migrants, miners, and health care workers.  Furthermore, human rights must be an intergral part of the 1893 
design, implementation and evaluation of an integrated and multisectoral response to TB.138  A human 1894 
rights approach to TB research is required to ensure that legislative and policy frameworks exist to 1895 
enable the widespread application of encouraging new scientific discoveries, provide accountability for 1896 
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R&D investments382 and remove barriers that preclude new TB research technologies being broadly 1897 
available for public benefit.383   1898 
 1899 
In addition to addressing legal frameworks that undermine TB control efforts, action must be taken  to 1900 
address TB stigma, which is pervasive throughout health  care systems.  Burdensome legal and 1901 
social practices that systematically infantilize, impoverish, and expose people with or at risk for TB must 1902 
be removed to end TB stigma.384,385 Public awareness campaigns that dispel  fears and promote positive 1903 
messages about TB, drawing on patient testimonials,  can aslso help reduce stigmatizing attitudes.386-388 1904 
388,389 Furthermore, campaigns that highlight the unfairness of obstacles faced by people who are sick 1905 
can evoke public support for greater investment in the welfare of stigmatized groups.390  Social 1906 
protection interventions, such as as conditional cash transfer  programs also can build resiliency to 1907 
stigma,76,391-393 especially among patients whose self-identity and social capital are linked to their ability 1908 
to sustain their families and themselves.394 It may also be useful to learn from and model successful 1909 
campaigns from HIV/AIDS, where community engagement, advocacy, and political buy-in have aligned 1910 
to ensure that policymaking and program planning mitigate stigma.   1911 
 1912 
4.7 WHO – a new role for a new era 1913 
With greater emphasis on sustainable domestic resources and the centrality of national health systems, 1914 
the SDG era also offers an opportunity to better define the role of WHO in ending the TB epidemic.  This 1915 
Commission has identified several priorities for which WHO can be a leading catalyst for change.  First, 1916 
technical assistance to countries and strategic leadership may not be unique to WHO, it must ensure 1917 
that critical technical assistance is available to member states.329 Second, the WHO global TB program 1918 
must catalyze a rethinking of TB surveillance systems and the use of data platforms.  In particular, WHO 1919 
has a crucial role to play in modernizing and expanding health information systems relevant to TB.  1920 
Incorporating routine reporting of social protection indices and non-health SDGs into global TB reports is 1921 
one key responsibility WHO has already embraced.365  However, by advocating for the better use of, 1922 
subnational, real-time data and dashboard technologies, including performance data,  the WHO can 1923 
encourage countries to use these systems to improve the quality and efficiency of their TB programs, 1924 
enable greater accountability, and facilitate more responsive and targeted technical assistance.   1925 
 1926 
WHO’s Director-General has repeatedly asserted the importance of UHC to his tenure,395 committing to 1927 
‘making universal health coverage happen in our lifetime.’396 Accordingly, WHO must continue to 1928 
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support robust TB programs as a central component of UHC.  To end TB, both a focused commitment to 1929 
TB activities and a progressive, inclusive vision of health care are essential.  WHO must wok to support 1930 
countries to hold these two complementary priorities in tension is critical.  1931 
 1932 
4.8 Establishing local, national, and global accountability 1933 
Turning written commitments into substantive actions requires an accountability framework that tracks 1934 
all elements of the TB response occurring at local, national and global levels. This framework must 1935 
measure progress towards ending TB worldwide and include timely reviews of results through 1936 
government and civil society accountability mechanisms, both national and global. It also must 1937 
incorporate a means for taking appropriate corrective actions.86   1938 
 1939 
At a national level, this Commission proposes a framework to ensure that accountability extends beyond 1940 
national TB programs and reports directly to Heads of State.  TB accountability should, as an exception, 1941 
be reported to Heads of State because of the health security risk that TB poses, and its adverse impact 1942 
on national economies and health systems.  Consistent with national strategic plans, such a framework 1943 
should include specific targets for reducing mortality and detecting more cases, screening populations at 1944 
high risk and scaling up access to preventive therapy, and addressing inequities in TB risk across 1945 
populations.  As highlighted earlier in this  report, country-specific targets deriving from the global 1946 
targets agreed upon at the UNHLM have been developed and  provide benchmarks that all countries 1947 
should achieve between 2018 and 2022.397  In addition the framework also needs to ensure that 1948 
financial resources are matched  to  achieving these targets.  Furthermore, it should engage ministers 1949 
across government to ensure multisectoral accountability on issues such as tobacco taxation and the 1950 
regulation of air pollution, as well as progress towards addressing relevant SDGs.  National TB 1951 
Commissions or cabinets that can monitor progress across sectors and/or ensure implementation of TB 1952 
specific national strategic plans may be appropriate in high-burden countries.   Enabling subnational 1953 
accountability, using regional data to highlight gaps in services and opportunities for allocative 1954 
efficiency, is also likely to be effective. Linking accountability mechanisms to financial resources that are 1955 
allocated separately from health budgets can enable responsive, targeted responses.  Such approaches 1956 
have proven effective in addressing the HIV/AIDS epidemic in several countries; 339 given the health 1957 
security risks and adverse economic impact of TB, similar approaches are justified to address the TB 1958 
epidemic in many high-burden countries. 1959 
 1960 
THE LANCET COMMISSION ON TUBERCULOSIS 
69 
 
Separate mechanisms must also include accountability for nation states at a global level.   We propose 1961 
that Heads of State should be accountable for their countries progress at the United Nations General 1962 
Assembly on a biannual basis.  Unfortunately, the political declaration arising from the UNHLM did not 1963 
include any specific accountability framework, but rather a commitment to support WHO to develop 1964 
such a framework at the level of the World Health Assembly.  As such, it is unclear that Heads of State 1965 
would be held to account for inaction to end this disease.  This Commission asserts that accountability at 1966 
the level of the UN, and independent of the WHO, offers the the best chance of driving global political 1967 
action and recommends that a report card be established to hold nations accountable for their 1968 
commitments and determine where additional assistance is needed.   This approach has been an 1969 
important political component of the global fight to end HIV/AIDS, as it has maintained global 1970 
recognition and financial investment to address this disease.  While the details of any national report 1971 
card would need to be drafted and approved to ensure stakeholder consensus, commitments on 1972 
accountability should include progress towards key End TB milestones and other relevant SDGs; 1973 
adoption and implementation of WHO recommended policies; registration of and access to the newest 1974 
and best medical tools; and TB financing. 86 Table 7, gives an example of a report card, highlighting the 1975 
current performance of ten high TB burden countries on several epidemiologic, programmatic, financial 1976 
and multisectoral indicators.   1977 
 1978 
Finally, OECD donor countries; international multilateral funding agencies such as the Global Fund and 1979 
UNITAID; non-governmental funders, like the Bill and Melinda Gates Foundation; and the agencies of 1980 
the United Nations, including WHO, UNICEF and UNAIDS all play vital roles in global efforts to end TB, 1981 
for which they also must be held to account.   Leveraging the Quality of ODA metrics already published 1982 
by the Center for Global Development Appendix Table xx provides a report card that highlights strengths 1983 
and weaknesses of major bilateral TB donors. Its purpose is to illustrate metrics on which these donors 1984 
can be evaluated.   Donor accountability to address DR-TB and TB R&D must be a focus in these report 1985 
cards, including the allocation of funds to address DR-TB related activities and/or the investment in TB 1986 
R&D.    Similar report cards for multilateral funders and major non-state actors are also necessary to 1987 
ensure that these institutions also are held accountable for their efforts towards ending the epidemic, 1988 
and to ensure that investments  are  syngergistic with domestic investments.  Enhanced accountability 1989 
of these institutions, not just to their board members or citizenry, but to TB survivors and their 1990 
advocates in recipient countries, represents a global public good.  While the indicators and governance 1991 
for these proposed report cards will need to be drafted and agreed to by consensus, dimensions should 1992 
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include performance monitoring and assessment, efficiency and effectiveness, sustainability, 1993 
transparency and responsiveness to corrective feedback.   1994 
 1995 
4.9 The Lancet TB Observatory 1996 
To spur political action and monitor progress towards ending TB after the United Nations High-Level 1997 
Meeting) on Tuberculosis, The Lancet Commission and experts participating in this Commission will 1998 
launch The Lancet TB Observatory.  The idea for this Observatory was first proposed in 201016 to 1999 
promote urgent global action to control the TB  epidemic.  It is needed now more than ever.  The 2000 
Observatory will be composed of global experts and stakeholders from high-burden countries and will 2001 
meet annually between now and 2022, to critically evaluate progress towards targets made at the UN 2002 
High-Level Meeting.  Leveraging the TB report card, it also will monitor domestic and global financing for 2003 
efforts to End TB and identify corrective actions and investments necessary  to achieve targets.  By 2004 
providing an independent perspective on the the activities of key global stakeholders, including WHO, 2005 
the Stop TB Partnership and the Global Fund, The Lancet TB Observatory can also help optimize 2006 
alignment of these different bodies towards ending the epidemic. 2007 
 2008 
2009 
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Section 5: Conclusions 2010 
We can build a TB-free world.  Many countries – even many low- and middle-income countries – have 2011 
demonstrated that that it is achievable, despite the limitations of existing tools. The prospect of a TB-2012 
free world is not a distant aspiration.  It is a realistic objective that can be achieved with the right 2013 
commitment of leadership and resources.  It will be a difficult task, with potential setbacks including the 2014 
challenge of drug-resistance, funding obstacles and uncertainties about the correct prioritization of tools 2015 
and implementation approaches.  However, the Commission hopes that the recommendations and 2016 
supporting evidence provided in this Report gives countries a roadmap to end their TB epidemics.  With 2017 
targeted, proven strategies, smart investments based on sound science, accelerated research and 2018 
development, and a shared responsibility, we can defeat TB within a generation. 2019 
 2020 
  2021 
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